Supplement I. Acute Pancreatitis Task Force on Quality:

Literature Review and Quality Indicator Descriptive Information

Care Plan Domain: DIAGNOSIS

Quality Indicator:

DIAG-1.1: IF a patient presents with acute onset severe upper abdominal pain with epigastric tenderness, THEN acute pancreatitis should be suspected, and serum lipase and/or amylase levels obtained.

obtailed.		
Clinical Recommendation	Acute pancreatitis should be susp	pected in a patient presenting with acute onset upper abdominal pain with
	epigastric tenderness. Serum lipa	se is useful for confirming the diagnosis of acute pancreatitis and levels
	elevated more than three times ab	pove upper limit of normal are diagnostic of acute pancreatitis.
Performance Target	98%	
Indicator Type (Structure/Process/	Process	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients presenting with characte	ristic abdominal pain
Rationale (i.e. How does the indicator	Timely diagnosis of acute pancre	atitis
lead to desired health outcome)?		
	Supportin	g Literature
Source		Methodology and GRADE
Tenner S, Baillie J, DeWitt J et al. An Gastroenterology Guideline: Manager	•	3- Expert opinion only Weak recommendation, likely to change as data becomes available
Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.		
2. Kiriyama T, Gabata T, Takada T et al. New diagnostic criteria of acute		3- Expert opinion only
pancreatitis. J Hepatobiliary Pancreat		Weak recommendation, likely to change as data becomes available
3. Shah AM, Eddi R, Kothari ST et al. A	*	2C Observational studies
serum lipase: a case series. JOP 2010; 11: 369 – 72		Very weak recommendation; alternative approaches are likely to be better under some circumstances
4. Rompianesi G, Hann A, Komolafe O,	Paraira SP Davidson RR	1C+ Observational studies
•		Strong recommendation, can apply to most practice settings in most situations
Gurusamy KS. Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis. Cochrane Database Syst		Strong recommendation, can apply to most practice settings in most steadtions
Rev. 2017 Apr 21; 4:CD012010. doi:		
10.1002/14651858.CD012010.pub2. Review.		
5. Lippi G, Valentino M, Cervellin G. La		3- Expert opinion only
pancreatitis: in search of the Holy Grail. Crit Rev Clin Lab Sci 2012; 49		Weak recommendation, likely to change as data becomes available
pancicaturs. In Search of the Hory Gran. Citt Kev Citi Lab Sci 2012, 49		The control of the co

	1, 18-31.	
6.	Banks PA, Bollen TL, Dervenis C et al. Classification of acute	3- Expert opinion only
	pancreatitis 2012: revision of Atlanta classification and definitions by	Weak recommendation, likely to change as data becomes available
	international consensus. Gut 2013; 62: 102 – 11.	
7.	Working Party of the British Society of Gastroenterology.; Association	3- Expert opinion only
	of Surgeons of Great Britain and Ireland.; Pancreatic Society of Great	Weak recommendation, likely to change as data becomes available
	Britain and Ireland.; Association of Upper GI Surgeons of Great Britain	
	and Ireland UK guidelines for the management of acute pancreatitis.	
	Gut. 2005 May; 54 Suppl 3:iii1-9. PubMed PMID: 15831893; PubMed	
	Central PMCID: PMC1867800.	
8.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3 Expert opinion only
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
	Acute pancreatitis: recent advances through randomised trials. Gut.	
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub	
	2017 Aug 24. Review. PubMed PMID: 28838972	
9.	Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of	3 Expert opinion only
	laboratory tests in acute pancreatitis. Am J Gastroenterol. 2002	Weak recommendation, likely to change as data becomes available
	Jun;97(6):1309-18. Review. PubMed PMID: 12094843.	
10	. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN;	3 Expert opinion only
	American Gastroenterological Association Institute Clinical Guidelines	Weak recommendation, likely to change as data becomes available
	Committee. American Gastroenterological Association Institute	
	Guideline on Initial Management of Acute Pancreatitis.	
	Gastroenterology. 2018 Mar;154(4):1096-1101. doi:	
	10.1053/j.gastro.2018.01.032. Epub 2018 Feb 3. PubMed PMID:	
	29409760.	

Care Plan Domain: DIAGNOSIS

Quality Indicator:

DIAG-1.2: IF a patient is suspected to have acute pancreatitis and the serum amylase and/or lipase levels are not diagnostic, THEN cross-sectional imaging (CT or MRI) should be performed to confirm acute pancreatitis and/or exclude an alternate diagnosis.

~			
		definitive diagnosis of acute pancreatitis is suspected and based on clinical	
	manifestations; but not confirmed by laboratory examination and ultrasound. CT enables visualization of		
*		creas free from the influence of gas bubbles in the alimentary tract and fatty	
	tissues in the abdominal wall and	cavity. CT and MRI are comparable in the early assessment of acute	
	pancreatitis.		
Performance Target	98%		
Indicator Type (Structure/Process/	Process, Appropriateness		
Outcome)			
Indicator Level (Hospital/Patient)	Patient		
Target Population	Patients presenting with characte	ristic abdominal pain in whom pancreatic enzymes are not diagnostic.	
Rationale (i.e. How does the indicator	Routine use of CT in patients	with acute pancreatitis is unwarranted since the diagnosis is apparent in	
lead to desired health outcome)?	many patients and most have a	a mild, uncomplicated course. However, if a definitive diagnosis of acute	
	pancreatitis cannot be made or	the basis of clinical manifestations and laboratory results, then CT	
	should be performed.		
	Supporting Literature		
Source		Methodology and GRADE	
1. Tenner S, Baillie J, DeWitt J et al. Ame	erican College of	3- Expert opinion only	
Gastroenterology Guideline: Managem	<u> </u>	Weak recommendation, likely to change as data becomes available	
Gastroenterol. 2013 Sep; 108(9):1400-	15; 1416.		
2. Kiriyama T, Gabata T, Takada T et al. 1		3- Expert opinion only	
pancreatitis. J Hepatobiliary Pancreat S	ci 2010; 17: 24 – 36.	Weak recommendation, likely to change as data becomes available	
3. Balthazar EJ. Acute pancreatitis: assess	sment of severity with clinical	3- Expert opinion only	
and CT evaluation. Radiology 2002; 223: 603 – 13.		Weak recommendation, likely to change as data becomes available	
4. Bollen TL, Singh VK, Maurer R et al. 0	Comparative evaluation of the	1C Observational studies	
modifi ed CT severity index and CT severity index in assessing severity of acute pancreatitis. AJR Am J Roentgenol 2011; 197: 386 – 92.		Intermediate-strength recommendation, may change when stronger evidence	
		is available	
5 Danles DA Dallan TI Damanis Cat al	Classification of souts	3- Expert opinion only	
5. Banks PA, Bollen TL, Dervenis C et al	. Classification of acute	3- Expert opinion only	

	international consensus. Gut 2013; 62: 102 – 11.	
6.	Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics	3- Expert opinion only
	Committee.; AGA Institute Governing Board AGA Institute technical	Weak recommendation, likely to change as data becomes available
	review on acute pancreatitis. Gastroenterology. 2007 May;132(5):2022-	
	44. Review. PubMed PMID: 17484894.	
7.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3- Expert opinion only
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
	Acute pancreatitis: recent advances through randomised trials. Gut.	
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub	
	2017 Aug 24. Review. PubMed PMID: 28838972	
8.	Dimastromatteo J, Brentnall T, Kelly KA. Imaging in pancreatic	3- Expert opinion only
	disease. Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):97-109. doi:	Weak recommendation, likely to change as data becomes available
	10.1038/nrgastro.2016.144. Epub 2016 Nov 9. Review. PubMed PMID:	
	27826137.	
9.	Arvanitakis M, Dumonceau JM, Albert J, et al. Endoscopic	3- Expert opinion only
	management of acute necrotizing pancreatitis: European Society of	Weak recommendation, likely to change as data becomes available
	Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary	
	guidelines. Endoscopy. 2018 Apr; 50: 524–546. doi:	
	https://doi.org/10.1055/a-0588-5365	

Care Plan Domain: DIAGNOSIS

Quality Indicator:

DIAG-1.3: IF a patient presents with at least 2 of the following 3 conditions, THEN a diagnosis of acute pancreatitis should be made:

- a. Acute onset upper abdominal pain with epigastric tenderness
- b. Serum pancreatic enzymes elevated greater than three times the upper limit of normal
- c. Findings consistent with acute pancreatitis on cross-sectional imaging (CT or MRI)

0		
Clinical Recommendation	Acute pancreatitis should be diagnosed on the basis of characteristic abdominal pain, elevated pancreatic	
	enzymes, and characteristic findings on imaging.	
Performance Target	98%	
Indicator Type (Structure/Process/ Process		
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients suspected to have acute pancreatitis	
Rationale (i.e. How does the indicator	cator Timely diagnosis of acute pancreatitis	
lead to desired health outcome)?		

	Supporting Literature		
Source		Methodology and GRADE	
1.	Tenner S, Baillie J, DeWitt J et al. American College of Gastroenterology Guideline: Management of Acute Pancreatitis. Am J Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
2.	Kiriyama T, Gabata T, Takada T et al. New diagnostic criteria of acute pancreatitis. J Hepatobiliary Pancreat Sci 2010; 17: 24 – 36.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
3.	Banks PA, Bollen TL, Dervenis C et al. Classification of acute pancreatitis 2012: revision of Atlanta classification and definitions by international consensus. Gut 2013; 62: 102 – 11.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
4.	Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA; LEADER Steering Committee.; LEADER Trial Investigators Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care. 2017 Jul;40(7):966-972. doi: 10.2337/dc16-2747. Epub 2017 May 5. PubMed PMID: 28476871	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings	

Quality Indicator:

ETIO-2.1: IF a patient is diagnosed with acute pancreatitis, THEN a thorough history including: (a) alcohol intake, (b) smoking, and (c) medications should be obtained and documented on presentation.

alconor intakc, (b) sinoking	, and (c) incurcations si	doubt be obtained and documented on presentation.
Clinical Recommendation		
	Particular emphasis should be pla	aced on duration (years) of heavy alcohol use and volume consumed daily.
	Acute pancreatitis may occur during alcohol withdrawal, and symptoms of alcohol withdrawal s	
	overlap with clinical evaluation of acute pancreatitis. The amount of alcohol considered to confer risk is greater	
	than 4-5 drinks per day in men, likely less in women, and binge drinking confers higher risk than continuous	
	drinking. Smoking is an additive	risk factor.
	A thorough history of smoking sh	nould be obtained from all patients diagnosed with acute pancreatitis. Particular
	emphasis should be placed on dur	ration (years) and current use (packs/day or equivalent).
	A definitive diagnosis of drug-ind	duced acute pancreatitis is often difficult. The medication being assigned as the
	contributory cause of acute pancr	reatitis must be described in terms of the dose, duration/latency, and the
	existence of rechallenge.	
Performance Target	a) 98.5%	
	b) 96.5%	
	c) 98%	
Indicator Type (Structure/Process/	Process	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients diagnosed with acute pancreatitis	
Rationale (i.e. How does the indicator	Establishing acute pancreatitis eti	iology is important because it determines management/treatment. A majority of
lead to desired health outcome)?	patients with alcoholic recurrent	acute pancreatitis develop chronic pancreatitis over a 15-year time course.
	Smoking is an additional, but poorly recognized, risk factor for recurrent acute and chronic pancreatitis.	
	Defining a drug as causing acute pancreatitis poses a challenge to clinicians.	
Supporting Literature		
Source		Methodology and GRADE
1. Kiriyama T, Gabata T, Takada T et a	l. New diagnostic criteria of acute	3- Expert opinion only
pancreatitis. J Hepatobiliary Pancreat	•	Weak recommendation, likely to change as data becomes available

2.	Bank S, Indaram A. Causes of acute and recurrent pancreatitis.	3- Expert opinion only
	Clinical considerations and clues to diagnosis. Gastroenterol Clin	Weak recommendation, likely to change as data becomes available
	North Am. 1999 Sep; 28(3):571-89, viii. Review.	
3.	Gullo L, Migliori M, Oláh A, Farkas G, Levy P, Arvanitakis C,	1C- Observational studies
	Lankisch P, Beger H. Acute pancreatitis in five European countries:	Intermediate-strength recommendation, may change when stronger evidence
	etiology and mortality. Pancreas. 2002 Apr; 24(3):223-7.	is available
4.	Tandon M, Topazian M. Endoscopic ultrasound in idiopathic acute	1C- Observational studies
	pancreatitis. Am J Gastroenterol. 2001 Mar; 96(3):705-9.	Intermediate-strength recommendation, may change when stronger evidence
		is available
5.	Whitcomb DC. Genetic polymorphisms in alcoholic pancreatitis. Dig	3- Expert opinion only
	Dis. 2005; 23(3-4):247-54. Review.	Weak recommendation, likely to change as data becomes available
6.	Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S.	3- Expert opinion only
	Drug-induced acute pancreatitis: an evidence-based review. Clin	Weak recommendation, likely to change as data becomes available
	Gastroenterol Hepatol. 2007 Jun; 5(6):648-61; quiz 644. Epub 2007	
	Mar 28. Review.	
7.	Al-Haddad M, Wallace MB. Diagnostic approach to patients with	3- Expert opinion only
	acute idiopathic and recurrent pancreatitis, what should be done?	Weak recommendation, likely to change as data becomes available
	World J Gastroenterol. 2008 Feb 21; 14(7):1007-10. Review.	
8.	Lowenfels AB, Maisonneuve P, Sullivan T. The changing character of	3- Expert opinion only
	acute pancreatitis: epidemiology, etiology, and prognosis. Curr	Weak recommendation, likely to change as data becomes available
	Gastroenterol Rep. 2009 Apr; 11(2):97-103. Review.	
9.	Ahmed Ali U, Issa Y, Hagenaars JC, Bakker OJ, van Goor H,	1C- Observational studies
	Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Brink	Intermediate-strength recommendation, may change when stronger evidence
	MA, et al. Risk of Recurrent Pancreatitis and Progression to Chronic	is available
	Pancreatitis After a First Episode of Acute Pancreatitis. Clin	
	Gastroenterol Hepatol. 2016 May;14 (5):738-46. doi:	
	10.1016/j.cgh.2015.12.040.	
10.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3- Expert opinion only
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
	Acute pancreatitis: recent advances through randomised trials. Gut.	
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub	
	2017 Aug 24. Review. PubMed PMID: 28838972	
11.	Coté GA, Yadav D, Slivka A, Hawes RH, Anderson MA, Burton FR,	1C- Observational studies
	Brand RE, Banks PA, Lewis MD, Disario JA, Gardner TB, Gelrud A,	Intermediate-strength recommendation, may change when stronger evidence
	Amann ST, Baillie J, Money ME, O'Connell M, Whitcomb DC,	is available
	Sherman S; North American Pancreatitis Study Group Alcohol and	

	smoking as risk factors in an epidemiology study of patients with	
	chronic pancreatitis. Clin Gastroenterol Hepatol. 2011 Mar;9(3):266-	
	73; quiz e27. doi: 10.1016/j.cgh.2010.10.015.	
12	Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle	3- Expert opinion only
	J. Drug-induced pancreatitis. Curr Gastroenterol Rep. 2012	Weak recommendation, likely to change as data becomes available
	Apr;14(2):131-8. doi: 10.1007/s11894-012-0245-9. Review. PubMed	
	PMID: 22314811	

Quality Indicator:

ETIO-2.2: IF a patient is diagnosed with acute pancreatitis, THEN a medical history should be obtained and documented to include: (a) previous attacks of acute or chronic pancreatitis and (b) family history of pancreatic disease.

J J I		
Clinical Recommendation	A medical history should include documentation of previous attacks and a family history of pancreatitis or	
	pancreatic cancer.	
Performance Target	a) 96.5%	
	b) 95%	
Indicator Type (Structure/Process/	Process	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	pulation Patients diagnosed with acute pancreatitis	
Rationale (i.e. How does the indicator		
lead to desired health outcome)?		

Supporting Literature	
Source	Methodology and GRADE
We did not find, in our search, literature to support this indicator. However, it is, in the opinion of our experts, a recommended clinical practice.	3- Expert opinion only Weak recommendation, likely to change as data becomes available

Quality Indicator:

ETIO-2.3: IF a patient is diagnosed with acute pancreatitis, THEN (a) serum liver chemistry, (b) triglyceride levels, (c) and serum calcium levels should be obtained on presentation.

trigiyeeride ieveis, (e) and s		ioulu de obtaineu on presentation.
		ncreatitis can be suggested by measuring serum bilirubin, ALT, AST & ALP at
the time of admission. Transient		elevation in one or more liver chemistries > 2-3x ULN is suggestive of acute
	biliary pancreatitis.	
	Baseline serum triglyceride level	s should be obtained in all patients with acute pancreatitis.
		nould be obtained in patients with acute pancreatitis. Elevated levels are
	associated with etiology, and low	v levels are associated with more severe disease.
Performance Target	a) 98%	
	b) 90%	
	c) 90%	
Indicator Type (Structure/Process/	Process, Efficiency	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients diagnosed with acute pa	nncreatitis
Rationale (i.e. How does the indicator		liagnosing acute biliary pancreatitis. Timely diagnosis of acute biliary
lead to desired health outcome)? pancreatitis facilitates timely surgical/endoscopic intervention.		gical/endoscopic intervention.
	Supportin	ng Literature
Source		Methodology and GRADE
1. Tenner S, Baillie J, DeWitt J et al. Am	nerican College of	3- Expert opinion only
Gastroenterology Guideline: Managen	nent of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available
Gastroenterol. 2013 Sep; 108(9):1400-	-15; 1416.	
2. Kiriyama T, Gabata T, Takada T et al.	New diagnostic criteria of acute	3- Expert opinion only
pancreatitis. J Hepatobiliary Pancreat Sci 2010; 17: 24 – 36.		Weak recommendation, likely to change as data becomes available
3. Bank S, Indaram A. Causes of acute and recurrent pancreatitis. Clinical		3- Expert opinion only
considerations and clues to diagnosis. Gastroenterol Clin North Am.		Weak recommendation, likely to change as data becomes available
1999 Sep; 28(3):571-89, viii. Review.		
4. Gullo L, Migliori M, Oláh A, Farkas C	•	1C- Observational studies
Lankisch P, Beger H. Acute pancreatitis in five European countries:		Intermediate-strength recommendation, may change when stronger evidence

	etiology and mortality. Pancreas. 2002 Apr; 24(3):223-7.	is available
5.	Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of	1C- Observational studies
	hyperlipidemic pancreatitis. Am J Gastroenterol. 1995 Dec;	Intermediate-strength recommendation, may change when stronger evidence
	90(12):2134-9.	is available
6.	Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin	3- Expert opinion only
	Gastroenterol. 2003 Jan; 36(1):54-62. Review.	Weak recommendation, likely to change as data becomes available
7.	Al-Haddad M, Wallace MB. Diagnostic approach to patients with acute	3- Expert opinion only
	idiopathic and recurrent pancreatitis, what should be done? World J	Weak recommendation, likely to change as data becomes available
	Gastroenterol. 2008 Feb 21; 14(7):1007-10. Review.	
8.	Johnson C, Lévy P. Detection of gallstones in acute pancreatitis: when	3- Expert opinion only
	and how? Pancreatology. 2010; 10(1):27-32. doi: 10.1159/000224147.	Weak recommendation, likely to change as data becomes available
	Epub 2010 Mar 19. Review.	
9.	Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting Mild-to-	1C- Observational studies
	Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. JAMA	Intermediate-strength recommendation, may change when stronger evidence
	Intern Med. 2016 Dec 1;176(12):1834-1842. doi:	is available
	10.1001/jamainternmed.2016.6875. PubMed PMID: 27820614	
10.	Tenner S, Dubner H, Steinberg W. Predicting gallstone pancreatitis	1C+ Overwhelming evidence from observational studies
	with laboratory parameters: a meta-analysis. Am J Gastroenterol. 1994	Strong recommendation; can apply to most practice settings in most situations
	Oct;89(10):1863-6. PubMed PMID: 7942684.	
11.	Trna J, Vege SS, Pribramska V, Chari ST, Kamath PS, Kendrick ML,	1C- Observational studies
	Farnell MB. Lack of significant liver enzyme elevation and gallstones	Intermediate-strength recommendation, may change when stronger evidence
	and/or sludge on ultrasound on day 1 of acute pancreatitis is associated	is available
	with recurrence after cholecystectomy: a population-based study.	
	Surgery. 2012 Feb;151(2):199-205. doi: 10.1016/j.surg.2011.07.017.	
	Epub 2011 Oct 5. PubMed PMID: 21975288.	
12.	Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am.	3- Expert opinion only
	1990 Dec; 19(4):783-91. Review. PubMed PMID: 2269517.	Weak recommendation, likely to change as data becomes available
13.	Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics	3- Expert opinion only
	Committee.; AGA Institute Governing Board AGA Institute technical	Weak recommendation, likely to change as data becomes available
	review on acute pancreatitis. Gastroenterology. 2007 May;132(5):2022-	
	44. Review. PubMed PMID: 17484894.	
14.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3- Expert opinion only
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
	Acute pancreatitis: recent advances through randomised trials. Gut.	
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub	
	2017 Aug 24. Review. PubMed PMID: 28838972	

15. Peng T, Peng X, Huang M, Cui J, Zhang Y, Wu H, Wang C. Serum	1C- Observational studies
calcium as an indicator of persistent organ failure in acute pancreatitis.	Intermediate-strength recommendation, may change when stronger evidence
Am J Emerg Med. 2017 Jul;35(7):978-982. doi:	is available
10.1016/j.ajem.2017.02.006. Epub 2017 Feb 4. PubMed PMID:	
28291705.	
16. Pokharel A, Sigdel PR, Phuyal S, Kansakar PBS, Vaidya P. Prediction	1C- Observational studies
of Severity of Acute Pancreatitis Using Total Serum Calcium and	Intermediate-strength recommendation, may change when stronger evidence
Albumin-Corrected Calcium: A Prospective Study in Tertiary Center	
Hospital in Nepal. Surg Res Pract. 2017;2017:1869091. doi:	
10.1155/2017/1869091. Epub 2017 Dec 19. PubMed PMID: 29410978;	
PubMed Central PMCID: PMC5749278.	
17. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in	1C- Observational studies
hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014	Intermediate-strength recommendation, may change when stronger evidence
Mar;48(3):195-203. doi: 10.1097/01.mcg.0000436438.60145.5a.	
Review. PubMed PMID: 24172179; PubMed Central PMCID:	
PMC3939000.	

Quality Indicator:

ETIO-2.4: IF a patient is diagnosed with acute pancreatitis and no clear etiology is evident after history, biochemical testing, and transabdominal ultrasound, THEN an elective CECT, EUS, and/or MRI with MRCP should be performed after the acute phase of pancreatitis has resolved.

Clinical Recommendation In adults with acute pancreatitis,		CECT, EUS, and MRI with MRCP are superior to transabdominal ultrasound
	for identifying structural etiologi	es for acute pancreatitis such as pre-malignant or malignant neoplasms.
Performance Target 96.5%		
Indicator Type (Structure/Process/	Process, Appropriateness	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients diagnosed with acute	pancreatitis with no clear etiology
Rationale (i.e. How does the indicator	Other causes such as pre-maligna	ant or malignant neoplasms should be considered a possible cause of acute
lead to desired health outcome)?	pancreatitis in patients with no cl	ear etiology.
	Supportin	ng Literature
Source		Methodology and GRADE
1. Tenner S, Baillie J, DeWitt J et al. Ar	merican College of	3- Expert opinion only
Gastroenterology Guideline: Manage	ment of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available
Gastroenterol. 2013 Sep; 108(9):1400)-15; 1416.	
2. Bank S, Indaram A. Causes of acute and recurrent pancreatitis. Clinical considerations and clues to diagnosis. Gastroenterol Clin North Am. 1999 Sep; 28(3):571-89, viii. Review.		3- Expert opinion only
		Weak recommendation, likely to change as data becomes available
3. Tandon M, Topazian M. Endoscopic	•	1C- Observational studies
pancreatitis. Am J Gastroenterol. 2001 Mar; 96(3):705-9.		Intermediate-strength recommendation, may change when stronger evidence is available
4. Al-Haddad M, Wallace MB. Diagnos	tic approach to patients with	3- Expert opinion only
acute idiopathic and recurrent pancrea		Weak recommendation, likely to change as data becomes available
World J Gastroenterol. 2008 Feb 21;	14(7):1007-10. Review.	
5. Munigala S, Kanwal F, Xian H, Sche	•	1C- Observational studies
of pancreatic adenocarcinoma after a	cute pancreatitis. Clin	Intermediate-strength recommendation, may change when stronger evidence
Gastroenterol Hepatol. 2014 Jul;12(7)):1143-1150.e1. doi:	is available
10.1016/j.cgh.2013.12.033. Epub 201	4 Jan 16. PubMed PMID:	

	24440214.	
6.	Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics Committee.; AGA Institute Governing Board AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007 May;132(5):2022-44. Review. PubMed PMID: 17484894.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
7.	Morales-Oyarvide V, Mino-Kenudson M, Ferrone CR, Gonzalez-Gonzalez LA, Warshaw AL, Lillemoe KD, Fernández-del Castillo C. Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. Surgery. 2015 Nov;158(5):1219-25. doi: 10.1016/j.surg.2015.04.029. PubMed PMID: 26077509.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
8.	Thorat A, Huang WH, Yeh TS, Jan YY, Hwang TL. Pancreatic ductal adenocarcinoma presenting with acute and chronic pancreatitis as initial presentation: is prognosis better? A comparison study. Hepatogastroenterology. 2014 Oct;61(135):2110-6. PubMed PMID: 25713917.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
9.	Thevenot A, Bournet B, Otal P, Canevet G, Moreau J, Buscail L. Endoscopic ultrasound and magnetic resonance cholangiopancreatography in patients with idiopathic acute pancreatitis. Dig Dis Sci. 2013 Aug;58(8):2361-8. doi: 10.1007/s10620-013-2632-y. Epub 2013 Mar 19. PubMed PMID: 23508982.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
10.	Rana SS, Bhasin DK, Rao C, Singh K. Role of endoscopic ultrasound in idiopathic acute pancreatitis with negative ultrasound, computed tomography, and magnetic resonance cholangiopancreatography. Ann Gastroenterol. 2012;25(2):133-137. PubMed PMID: 24714266; PubMed Central PMCID: PMC3959389.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available

Quality Indicator:

ETIO-2.5: IF a patient is diagnosed with acute pancreatitis, THEN ERCP is not recommended purely for determination of etiology.

purely for determination of enology.				
			estimated to be low for patients with acute pancreatitis who have a normal	
endoscopic		•	ndoscopic ultrasound, MRI with MRCP, or both. The role of ERCP in the setting of idiopathic acute	
	pancreatitis remains controversia		ત્રી.	
Per	rformance Target	2%		
Ind	licator Type (Structure/Process/	Process, Appropriateness		
Ou	tcome)			
Ind	licator Level (Hospital/Patient)	Patient		
Tai	rget Population	Patients diagnosed with acute pa	ancreatitis	
Rat	tionale (i.e. How does the indicator		estimated to be low for patients with acute pancreatitis who have a normal	
lea	d to desired health outcome)?	endoscopic ultrasound, MRI with	h MRCP, or both	
		Supportin	ng Literature	
Source			Methodology and GRADE	
1.	Wilcox, C.M., Varadarajulu, S. and E	Eloubeidi, M. (2006) Role of	3- Expert opinion only	
	Endoscopic Evaluation in Idiopathic	Pancreatitis: A Systematic	Weak recommendation, likely to change as data becomes available	
	Review. Gastrointestinal Endoscopy,	63, 1037-1045.		
	http://dx.doi.org/10.1016/j.gie.2006.0	02.024.		
2.	Mariani A, Arcidiacono PG, Curioni	S, Giussani A, Testoni PA.	1C- Observational studies	
	Diagnostic yield of ERCP and secreti	in-enhanced MRCP and EUS in	Intermediate-strength recommendation, may change when stronger evidence	
	patients with acute recurrent pancreat		is available	
Liver Dis. 2009 Oct;41(10):753-8. doi: 10.1016/j.dld.2009.01.009.		· ·		
	Epub 2009 Mar 10. PubMed PMID:			
3.	Das R, Clarke B, Tang G, Papachristo		1C- Observational studies	
	Yadav D. Endoscopic sphincterotomy		Intermediate-strength recommendation, may change when stronger evidence	
	history of idiopathic recurrent acute p		is available	
	Pancreatology. 2016 Sep-Oct;16(5):7			
	10.1016/j.pan.2016.07.009. Epub 201	16 Jul 14. PubMed PMID:		
	27450967.			

Quality Indicator:

ETIO-2.6: IF a patient is diagnosed with acute pancreatitis and the etiology remains unknown after history, biochemical testing, and cross-sectional imaging, THEN the patient should be referred to a pancreatic center of excellence.

Parior carre control of chicons			
Clinical Recommendation	-	idiopathic if there is no established etiology after history, biochemical testing,	
	and cross-sectional imaging (e.g., transabdominal US, CECT, MRI with MRCP, and/or EUS). The patient should be referred to a tertiary care center with expertise in medical pancreatology. There is debate as to		
	whether one should wait until the	e second attack to refer.	
Performance Target	77.5%		
Indicator Type (Structure/Process/	Process		
Outcome)			
Indicator Level (Hospital/Patient)	Patient		
Target Population	Patients diagnosed with acute pancreatitis in whom the etiology is unclear after thorough diagnostic work-up		
Rationale (i.e. How does the indicator	Patients with idiopathic acute par	ncreatitis require specialized care. Establishing acute pancreatitis etiology is	
lead to desired health outcome)?	important because it determines	es management/treatment.	
	Supportin	ng Literature	
Source		Methodology and GRADE	
1. Tenner S, Baillie J, DeWitt J et al. A	merican College of	3- Expert opinion only	
Gastroenterology Guideline: Management of Acute Pancreatitis. Am J Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.		Weak recommendation, likely to change as data becomes available	
2. Bank S, Indaram A. Causes of acute	and recurrent pancreatitis.	3- Expert opinion only	
Clinical considerations and clues to d	liagnosis. Gastroenterol Clin	Weak recommendation, likely to change as data becomes available	
North Am. 1999 Sep; 28(3):571-89,	viii. Review.		
3. Tandon M, Topazian M. Endoscopic ultrasound in idiopathic acute pancreatitis. Am J Gastroenterol. 2001 Mar; 96(3):705-9.		1C- Observational studies	
		Intermediate-strength recommendation, may change when stronger evidence is available	
4. Al-Haddad M, Wallace MB. Diagnos	stic approach to patients with	3- Expert opinion only	
acute idiopathic and recurrent pancre	atitis, what should be done?	Weak recommendation, likely to change as data becomes available	
World J Gastroenterol. 2008 Feb 21;	14(7):1007-10. Review.		
5. Johnson C, Lévy P. Detection of gallstones in acute pancreatitis: when		3- Expert opinion only	

	and how? Pancreatology. 2010; 10(1):27-32. doi: 10.1159/000224147.	Weak recommendation, likely to change as data becomes available
	Epub 2010 Mar 19. Review.	
6.	Sheth SG, Conwell DL, Whitcomb DC, Alsante M, Anderson MA,	3- Expert opinion only
	Barkin J, Brand R, Cote GA, Freedman SD, Gelrud A, Gorelick F, Lee	Weak recommendation, likely to change as data becomes available
	LS, Morgan K, Pandol S, Singh VK, Yadav D, Wilcox CM, Hart PA.	
	Academic Pancreas Centers of Excellence: Guidance from a	
	multidisciplinary chronic pancreatitis working group at PancreasFest.	
	Pancreatology. 2017 May - Jun;17(3):419-430. doi:	
	10.1016/j.pan.2017.02.015. Epub 2017 Feb 28. PubMed PMID:	
	28268158; PubMed Central PMCID: PMC5525332.	

Care Plan Domain: INITIAL ASSESSMENT AND RISK STRATIFICATION

Quality Indicator:

RISK-3.1: IF a patient is diagnosed with acute pancreatitis, THEN intravascular volume depletion/hemoconcentration (orthostatic vital signs, hematocrit, BUN, creatinine) should be assessed and documented.

and documented.		
Patients with acute pancreatitis should be assessed for hemodynamic status immediately upon presentation, and		
resuscitative measures begun as n	eeded.	
98.5%		
Process		
Patient and hospital		
Patients diagnosed with acute pancreatitis		
Rationale (i.e. How does the indicator		
Supporting Literature		
	Methodology and GRADE	
	resuscitative measures begun as n 98.5% Process Patient and hospital Patients diagnosed with acute par Early resuscitation is linked to be	

	2.5FF		
	Source	Methodology and GRADE	
f	1. Tenner S, Baillie J, DeWitt J et al. American College of	3- Expert opinion only	
	Gastroenterology Guideline: Management of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available	
	Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.		
Ī	2. Mounzer R et al. Comparison of existing clinical scoring systems to	1C- Observational studies	
	predict persistent organ failure in patients with acute pancreatitis.	Intermediate-strength recommendation, may change when stronger evidence	
	Gastroenterology 2012; 142: 1476 – 82.	is available	
Ī	3. Brown A, Orav J, Banks PA. Hemoconcentration is an early marker for	1C- Observational studies	
	organ failure and necrotizing pancreatitis. Pancreas 2000; 20: 367 – 72.	Intermediate-strength recommendation, may change when stronger evidence	
		is available	
Ī	4. Wu BU, Johannes RS, Sun X et al. Early changes in blood urea	1C- Observational studies	
	nitrogen predict mortality in acute pancreatitis. Gastroenterology 2009;	Intermediate-strength recommendation, may change when stronger evidence	
	137: 129 – 35.	is available	
Ī	5. Gardner TB, Olenec CA, Chertoff JD, Mackenzie TA, Robertson DJ.	1C- Observational studies	
	Hemoconcentration and pancreatic necrosis: further defining the	Intermediate-strength recommendation, may change when stronger evidence	
	relationship. Pancreas. 2006 Aug; 33(2):169-73. PubMed PMID:	is available	
	16868483.		

6.	Lankisch PG, Mahlke R, Blum T, Bruns A, Bruns D, Maisonneuve P, Lowenfels AB. Hemoconcentration: an early marker of severe and/or necrotizing pancreatitis? A critical appraisal. Am J Gastroenterol. 2001 Jul;96(7):2081-5. PubMed PMID: 11467635.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
7.	Baillargeon JD, Orav J, Ramagopal V, Tenner SM, Banks PA. Hemoconcentration as an early risk factor for necrotizing pancreatitis. Am J Gastroenterol. 1998 Nov; 93(11):2130-4. PubMed PMID: 9820385.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
8.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group Acute pancreatitis: recent advances through randomised trials. Gut. 2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub 2017 Aug 24. Review. PubMed PMID: 28838972	3- Expert opinion only Weak recommendation, likely to change as data becomes available
9.	Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol. 2002 Jun;97(6):1309-18. Review. PubMed PMID: 12094843.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
	Koutroumpakis E, Wu BU, Bakker OJ, Dudekula A, Singh VK, Besselink MG, Yadav D, Mounzer R, van Santvoort HC, Whitcomb DC, Gooszen HG, Banks PA, Papachristou GI. Admission Hematocrit and Rise in Blood Urea Nitrogen at 24 h Outperform other Laboratory Markers in Predicting Persistent Organ Failure and Pancreatic Necrosis in Acute Pancreatitis: A Post Hoc Analysis of Three Large Prospective Databases. Am J Gastroenterol. 2015 Dec;110(12):1707-16. doi: 10.1038/ajg.2015.370. Epub 2015 Nov 10. Erratum in: Am J Gastroenterol. 2016 Aug;111(8):1216. Mounzer, Rawad [added]. PubMed PMID: 26553208.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
11.	Lankisch PG, Weber-Dany B, Hebel K, Maisonneuve P, Lowenfels AB. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. Clin Gastroenterol Hepatol. 2009 Jun;7(6):702-5; quiz 607. doi: 10.1016/j.cgh.2009.02.020. Epub 2009 Feb 24. PubMed PMID: 19245846.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
12.	Aggarwal A, Manrai M, Kochhar R. Fluid resuscitation in acute pancreatitis. World J Gastroenterol. 2014 Dec 28;20(48):18092-103. doi: 10.3748/wjg.v20.i48.18092. Review. PubMed PMID: 25561779; PubMed Central PMCID: PMC4277949.	3- Expert opinion only Weak recommendation, likely to change as data becomes available

Care Plan Domain: INITIAL ASSESSMENT AND RISK STRATIFICATION

Quality Indicator:

RISK-3.2: IF a patient is diagnosed with acute pancreatitis, THEN indicators for severity (organ failure, SIRS, age, impaired mental status, and pleural effusion) should be assessed and documented on presentation.

Clinical Recommendation	Patients with acute pancreatitis should be stratified based on severity, into higher and lower risk categories.	
Performance Target	98%	
Indicator Type (Structure/Process/	Process	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients diagnosed with acute pancreatitis	
Rationale (i.e. How does the indicator	Risk stratification informs triage, management, and admission criteria e.g. admission to critical care units.	
lead to desired health outcome)?		

	Supporting Literature		
	Source	Methodology and GRADE	
1.	Tenner S, Baillie J, DeWitt J et al. American College of Gastroenterology Guideline: Management of Acute Pancreatitis. Am J Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
2.	Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and CT evaluation. Radiology 2002; 223: 603 – 13.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
3.	Banks PA, Bollen TL, Dervenis C et al. Classification of acute pancreatitis 2012: revision of Atlanta classification and definitions by international consensus. Gut 2013; 62: 102 – 11.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
4.	Dellinger EP, Forsmark CE, Layer P et al. Determinant-Based Classification of Acute Pancreatitis Severity: An International Multidisciplinary Consultation. Ann Surg 2012; 256: 875 – 880.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
5.	Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006; 101: 2379 – 400.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
6.	Tenner S. Initial management of acute pancreatitis: critical issues during the first 72 hours. Am J Gastroenterol 2004; 99: 2489 – 94.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
7.	Heller SJ, Noordhoek E, Tenner SM et al. Pleural effusion as a	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence	

predictor of severity in acute pancreatitis . Pancreas 1997; 15: 222 – 5.	is available
8. Wu BU, Johannes RS, Sun X et al. Early changes in blood urea nitrogen predict mortality in acute pancreatitis. Gastroenterology 2009; 137: 129 – 35.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
9. Lankisch PG, Mahlke R, Blum T, Bruns A, Bruns D, Maisonneuve P, Lowenfels AB. Hemoconcentration: an early marker of severe and/or necrotizing pancreatitis? A critical appraisal. Am J Gastroenterol. 2001 Jul;96(7):2081-5. PubMed PMID: 11467635.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
10. Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics Committee.; AGA Institute Governing Board AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007 May;132(5):2022-44. Review. PubMed PMID: 17484894.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
11. van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group Acute pancreatitis: recent advances through randomised trials. Gut. 2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub 2017 Aug 24. Review. PubMed PMID: 28838972	3 Expert opinion only Weak recommendation, likely to change as data becomes available
12. Andersson B, Olin H, Eckerwall G, Andersson R. Severe acute pancreatitisoutcome following a primarily non-surgical regime. Pancreatology. 2006;6(6):536-41. Epub 2006 Nov 10. PubMed PMID: 17106218.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
13. Koutroumpakis E, Wu BU, Bakker OJ, Dudekula A, Singh VK, Besselink MG, Yadav D, Mounzer R, van Santvoort HC, Whitcomb DC, Gooszen HG, Banks PA, Papachristou GI. Admission Hematocrit and Rise in Blood Urea Nitrogen at 24 h Outperform other Laboratory Markers in Predicting Persistent Organ Failure and Pancreatic Necrosis in Acute Pancreatitis: A Post Hoc Analysis of Three Large Prospective Databases. Am J Gastroenterol. 2015 Dec;110(12):1707-16. doi: 10.1038/ajg.2015.370. Epub 2015 Nov 10. Erratum in: Am J Gastroenterol. 2016 Aug;111(8):1216. Mounzer, Rawad [added]. PubMed PMID: 26553208.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
14. Lankisch PG, Weber-Dany B, Hebel K, Maisonneuve P, Lowenfels AB. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. Clin Gastroenterol Hepatol. 2009 Jun;7(6):702-5; quiz 607. doi: 10.1016/j.cgh.2009.02.020. Epub 2009 Feb 24. PubMed PMID: 19245846.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
15. Muddana V, Whitcomb DC, Khalid A, Slivka A, Papachristou GI.	1C- Observational studies

Elevated serum creatinine as a marker of pancreatic necrosis in acute pancreatitis. Am J Gastroenterol. 2009 Jan;104(1):164-70. doi: 10.1038/ajg.2008.66. PubMed PMID: 19098865.	Intermediate-strength recommendation, may change when stronger evidence is available
16. Papachristou GI, Papachristou DJ, Avula H, Slivka A, Whitcomb DC. Obesity increases the severity of acute pancreatitis: performance of APACHE-O score and correlation with the inflammatory response. Pancreatology. 2006;6(4):279-85. Epub 2006 Apr 19. PubMed PMID: 16636600.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
17. Aggarwal A, Manrai M, Kochhar R. Fluid resuscitation in acute pancreatitis. World J Gastroenterol. 2014 Dec 28;20(48):18092-103. doi: 10.3748/wjg.v20.i48.18092. Review. PubMed PMID: 25561779; PubMed Central PMCID: PMC4277949.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
18. Singh VK, Wu BU, Bollen TL, Repas K, Maurer R, Mortele KJ, Banks PA. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1247-51. doi: 10.1016/j.cgh.2009.08.012. Epub 2009 Aug 15. PubMed PMID: 19686869.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
19. Gao W, Yang H-X, & Ma C-E. The Value of BISAP Score for Predicting Mortality and Severity in Acute Pancreatitis: A Systematic Review and Meta-Analysis. PLOS ONE. 2015 Jun:1-15; doi:10.1371/journal.pone.0130412	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available

Care Plan Domain: INITIAL ASSESSMENT AND RISK STRATIFICATION

Quality Indicator:

RISK-3.3: IF a patient is diagnosed with acute pancreatitis and has SIRS and/or organ failure, THEN they should be documented to be at risk for severe acute pancreatitis.

Tilli tilly bliddle of dott	incliced to be at 11511 10	1 Severe acute patier carries.
Clinical Recommendation Clinical scoring systems can pred		dict persistent organ failure in patients with acute pancreatitis.
Performance Target 90%		
Indicator Type (Structure/Process/	Process	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients diagnosed with acute pa	ncreatitis
Rationale (i.e. How does the indicator	It is important to identify patients	s with acute pancreatitis who are at risk for developing persistent organ failure
lead to desired health outcome)?	and severe pancreatitis early in the	ne course of disease.
	Supportir	ng Literature
Source		Methodology and GRADE
20. Tenner S, Baillie J, DeWitt J et al. American College of Gastroenterology Guideline: Management of Acute Pancreatitis. Am J Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.		3- Expert opinion only Weak recommendation, likely to change as data becomes available
21. Banks PA, Bollen TL, Dervenis C et al. Classification of acute pancreatitis 2012: revision of Atlanta classification and definitions by international consensus. Gut 2013; 62: 102 – 11.		3- Expert opinion only Weak recommendation, likely to change as data becomes available
22. Dellinger EP, Forsmark CE, Layer P et al. Determinant-Based Classification of Acute Pancreatitis Severity: An International Multidisciplinary Consultation. Ann Surg 2012; 256: 875 – 880.		3- Expert opinion only Weak recommendation, likely to change as data becomes available
23. Mounzer R et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. Gastroenterology 2012; 142: 1476 – 82.		1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
24. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006; 101: 2379 – 400.		3- Expert opinion only Weak recommendation, likely to change as data becomes available
25. Tenner S. Initial management of acute pancreatitis: critical issues		3- Expert opinion only
during the first 72 hours. Am J Gastroenterol 2004; 99: 2489 – 94.		Weak recommendation, likely to change as data becomes available
26. Mofidi R, Duff MD, Wigmore SJ et al. Association between early		1C- Observational studies
systemic inflammatory response, seve	_	Intermediate-strength recommendation, may change when stronger evidence
and death in acute pancreatitis . Br J Surg 2006; 93: 738 – 44.		is available
and death in dedic panerealitis. Di 3 burg 2000, 73. 130 – 44.		10 WYMIMOID

27. Buter A, Imrie CW, Carter CR et al. Dynamic nature of early organ	1C- Observational studies
dysfunction determines outcome in acute pancreatitis .Br J Surg 2002;	Intermediate-strength recommendation, may change when stronger evidence
89 :298 – 302	is available
28. Park JY, Jeon TJ, Ha TH et al. Bedside index for severity in acute	1C- Observational studies
pancreatitis:comparison with other scoring systems in predicting	Intermediate-strength recommendation, may change when stronger evidence
severity and organ failure. Hepatobiliary Panreat Dis Int. 2013 Dec;	is available
12(6): 645-50	
29. Bollen TL, Singh VK, Maurer R et al. Comparative evaluation of the	1C- Observational studies
modified CT severity index and CT severity index in assessing severity	Intermediate-strength recommendation, may change when stronger evidence
of acute pancreatitis. AJR Am J Roentgenol 2011; 197: 386 – 92.	is available
30. Chen L, Lu G, Zhou Q, & Zhan Q. Evaluation of the BISAP Score in	1C- Observational studies
Predicting Severity and Prognoses of Acute Pancreatitis in Chinese	Intermediate-strength recommendation, may change when stronger evidence
Patients. Int Surg 2013; 98:6-12	is available
31. Senapati, D, Debata PK, Jenasamant SS et al. A prospective study of	1C- Observational studies
the Bedside Index for Severity in Acute Pancreatitis (BISAP) score in	Intermediate-strength recommendation, may change when stronger evidence
acute pancreatitis: An Indian perspective. Pancreatology 2014; 335-339	is available
32. Kim BG, Noh MH, Ryu CH et al. A comparison of the BISAP score	1C- Observational studies
and serum procalcitonin for predicting the severity of acute pancreatitis.	Intermediate-strength recommendation, may change when stronger evidence
Korean J Intern Med 2013; 28:322-329	is available
33. Oskarsson V, Mehrabi M, Orsini N et al. Validation of the Harmless	1C- Observational studies
Acute Pancreatitis Score in Predicting Non-severe Course of Acute	Intermediate-strength recommendation, may change when stronger evidence
Pancreatitis. Pancreatology 2011; 11:464-468	is available
34. Papachristou GI, Muddana V, Yadav D, O'Connell M, Sanders MK,	1C- Observational studies
Slivka A, Whitcomb DC. Comparison of BISAP, Ranson's, APACHE-	Intermediate-strength recommendation, may change when stronger evidence
II, and CTSI scores in predicting organ failure, complications, and	is available
mortality in acute pancreatitis. Am J Gastroenterol. 2010	
Feb;105(2):435-41; quiz 442. doi: 10.1038/ajg.2009.622.	
35. Wu BU, Johannes RS, Sun X et al. The early prediction of mortality in	1C- Observational studies
acute pancreatitis: a large population-based study. Gut 2008; 57:	Intermediate-strength recommendation, may change when stronger evidence
1698Y1703.	is available
36. Freeman MF, Werner J, van Santvoort HC et al. Interventions for	3- Expert opinion only
necrotizing pancreatitis. Summary of a multidisciplinary consensus	Weak recommendation, likely to change as data becomes available
conference. Pancreas 2012; 8: 1176 – 94.	
37. Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics	3- Expert opinion only
Committee.; AGA Institute Governing Board AGA Institute technical	Weak recommendation, likely to change as data becomes available

review on acute pancreatitis. Gastroenterology. 2007 May;132(5):2022-	
44. Review. PubMed PMID: 17484894.	
38. van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3- Expert opinion only
Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
Acute pancreatitis: recent advances through randomised trials. Gut.	
2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub	
2017 Aug 24. Review. PubMed PMID: 28838972	
39. Halonen KI, Pettilä V, Leppäniemi AK, Kemppainen EA, Puolakkainen	1C- Observational studies
PA, Haapiainen RK. Multiple organ dysfunction associated with severe	Intermediate-strength recommendation, may change when stronger evidence
acute pancreatitis. Crit Care Med. 2002 Jun;30(6):1274-9. PubMed	is available
PMID: 12072681.	
40. Koutroumpakis E, Wu BU, Bakker OJ, Dudekula A, Singh VK,	1C- Observational studies
Besselink MG, Yadav D, Mounzer R, van Santvoort HC, Whitcomb	Intermediate-strength recommendation, may change when stronger evidence
DC, Gooszen HG, Banks PA, Papachristou GI. Admission Hematocrit	is available
and Rise in Blood Urea Nitrogen at 24 h Outperform other Laboratory	
Markers in Predicting Persistent Organ Failure and Pancreatic Necrosis	
in Acute Pancreatitis: A Post Hoc Analysis of Three Large Prospective	
Databases. Am J Gastroenterol. 2015 Dec;110(12):1707-16. doi:	
10.1038/ajg.2015.370. Epub 2015 Nov 10. Erratum in: Am J	
Gastroenterol. 2016 Aug;111(8):1216. Mounzer, Rawad [added].	
PubMed PMID: 26553208.	

Care Plan Domain: INITIAL MANAGEMENT (BASELINE- 72 HRS)

Quality Indicator:

MGMT-4.1: IF a patient is diagnosed with acute pancreatitis, THEN fluid resuscitation should be initiated (with bolus and maintenance) within 2 hours of the time of diagnosis as directed by assessment of intravascular volume/hemoconcentration.

appendiction in the avancata	voidine, incline concentr	i uu viii
Clinical Recommendation	Early aggressive intravenous hydration should be initiated within 12-24 hours in patients with acute pancreatitis	
	Patients should receive an initial	volume challenge with a bolus of 20cc/kg of crystalloid over 60-90 minutes.
Performance Target	96.5%	
Indicator Type (Structure/Process/	Process, Efficiency	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients diagnosed with acute pa	ncreatitis
Rationale (i.e. How does the indicator	Early aggressive intravenous hyd	dration is most beneficial in the first 12-24 hours and may have little benefit
lead to desired health outcome)?	beyond.	
	Supportin	ng Literature
Source		Methodology and GRADE
1. Tenner S, Baillie J, DeWitt J et al. Am	nerican College of	3- Expert opinion only
Gastroenterology Guideline: Managen	nent of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available
Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.		
2. Tenner S. Initial management of acute	pancreatitis: critical issues	3- Expert opinion only
during the first 72 hours. Am J Gastroenterol 2004; 99: 2489 – 94.		Weak recommendation, likely to change as data becomes available
3. Fisher JM & Gardner T. The "Golden	Hours" of Management of Acute	3- Expert opinion only
Pancreatitis. Am J Gastroenterol 2012:107:1146-1150		Weak recommendation, likely to change as data becomes available
4. Warndorf MG, Kurtzman JT, Bartel M	IJ et al. Early fluid resuscitation	1C- Observational studies
reduces morbidity among patients with	n acute pancreatitis. Clin	Intermediate-strength recommendation, may change when stronger evidence
Gastroenterol Hepatol 2011; 9:705 –	. 9	is available
5. Gardner TB, Vege SS, Pearson RK et		3- Expert opinion only
pancreatitis. Clin Gastroenterol Hepatol 2008; 6: 1070 – 6.		Weak recommendation, likely to change as data becomes available
6. Gardner TB, Vege SS, Chari ST et al.		1C- Observational studies
resuscitation in severe acute pancreation	-	Intermediate-strength recommendation, may change when stronger evidence
mortality. Pancreatology 2009; 9: 770	<i>−</i> 6.	is available
7. Wu BU, Hwang JQ, Gardner TH et al. Lactated Ringer's solution		1A/1B- Randomized trials without/with important limitations

reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol 2011; 9: 710 – 7.	Strong recommendation, likely to apply to most practice settings
8. Wu BU and Conwell DL. Acute Pancreatitis Part I: Approach to Early Management. Clin Gastro Gastroenterol. 2010 May; 8:410-416.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
9. Wall I, Badalov N, Baradarian R et al. Decreased morbidity and mortality in patients with acute pancreatitis related to aggressive intravenous hydration. Pancreas 2011; 40: 547 – 50.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
10. Buxbaum JL, Quezada M, Da B, et al. Early Aggressive Hydration Hastens Clinical Improvement in Mild Acute Pancreatitis. Am J Gastroenterol 2017; 112:797-803.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most practice settings
11. Singh VK, Gardner TB, Papachristou GI, et al. An international multicenter study of early intravenous fluid administration and outcome in acute pancreatitis. United European Gastroenterology Journal 2017; 5 (4): 491-498.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
12. Bakker OJ, Issa Y, van Santvoort HC, et al. Treatment options for acute pancreatitis. Nat Rev Gastroenterol Hepatol 11, 462-469 (2014).	3- Expert opinion only Weak recommendation, likely to change as data becomes available
13. Brown A, Orav J, Banks PA. Hemoconcentration is an early marker for organ failure and necrotizing pancreatitis. Pancreas 2000; 20: 367 – 72.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
 14. Thomas Kerner et al. Determinants of Pancreatic Microcirculation in Acute Pancreatitis in Rats. Journal of Surgical Research. 1996; 62: 165 171 	2C-Observational studies Very weak recommendation; alternative approaches are likely to be better under some circumstances
15. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. Gastroenterology. 2007 Mar; 132(3):1127-51. Review. Erratum in: Gastroenterology. 2007 Sep; 133(3):1056. PubMed PMID: 17383433.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
16. Nasr JY, Papachristou GI. Early fluid resuscitation in acute pancreatitis: a lot more than just fluids. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):633-4. doi: 10.1016/j.cgh.2011.03.010. Epub 2011 Mar 21. PubMed PMID: 21421079.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
17. Baillargeon JD, Orav J, Ramagopal V, Tenner SM, Banks PA. Hemoconcentration as an early risk factor for necrotizing pancreatitis. Am J Gastroenterol. 1998 Nov; 93(11):2130-4. PubMed PMID: 9820385.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
18. Aggarwal A, Manrai M, Kochhar R. Fluid resuscitation in acute pancreatitis. World J Gastroenterol. 2014 Dec 28;20(48):18092-103. doi: 10.3748/wjg.v20.i48.18092. Review. PubMed PMID: 25561779;	3- Expert opinion only Weak recommendation, likely to change as data becomes available

PubMed Central PMCID: PMC4277949.	
19. Mentula P, Leppäniemi A. Position paper: timely interventions in	3- Expert opinion only
severe acute pancreatitis are crucial for survival. World J Emerg Surg.	Weak recommendation, likely to change as data becomes available
2014 Feb 10;9(1):15. doi: 10.1186/1749-7922-9-15. PubMed PMID:	
24512891; PubMed Central PMCID: PMC3926684.	
20. Eastridge BJ, Salinas J, McManus JG, Blackburn L, Bugler EM, Cooke	1C- Observational studies
WH, Convertino VA, Wade CE, Holcomb JB. Hypotension begins at	Intermediate-strength recommendation, may change when stronger evidence
110 mm Hg: redefining "hypotension" with data. J Trauma. 2007	is available
Aug;63(2):291-7; discussion 297-9. Erratum in: J Trauma. 2008	
Aug;65(2):501. Concertino, Victor A [corrected to Convertino, Victor	
A]. PubMed PMID: 17693826.	
21. Yamashita T, Horibe M, Sanui M, Sasaki M, et al. Large Volume Fluid	1C- Observational studies
Resuscitation for Severe Acute Pancreatitis is Associated with Reduced	Intermediate-strength recommendation, may change when stronger evidence
Mortality. J Clin Gastroenterol. 2018	is available

Care Plan Domain: INITIAL MANAGEMENT (BASELINE- 72 HRS)

Quality Indicator:

MGMT-4.2: IF a patient is diagnosed with acute pancreatitis, THEN Lactated Ringer's solution should be the preferred crystalloid replacement fluid unless contraindicated.

St	lould be the preferred cry	stalloid replacement fl	uid unless contraindicated.		
Cl	inical Recommendation	Lactated Ringer's may be the preferred crystalloid replacement fluid for acute pancreatitis patients.			
Pe	Performance Target 80%				
In	Indicator Type (Structure/Process/ Process				
Oı	itcome)				
In	dicator Level (Hospital/Patient)	Patient			
Ta	rget Population	Patients with acute pancreatitis			
Ra	tionale (i.e. How does the indicator	Early aggressive intravenous hyd	Iration is most beneficial in the first 12-24 hours and Lactated Ringer's is the		
lea	d to desired health outcome)?	preferred replacement fluid.			
	Supporting Literature				
	Source		Methodology and GRADE		
1.	Tenner S, Baillie J, DeWitt J et al. Am	erican College of	3- Expert opinion only		
	Gastroenterology Guideline: Managen	9	Weak recommendation, likely to change as data becomes available		
	Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.				
2.	2. Fisher JM & Gardner T. The "Golden Hours" of Management of Acute		3- Expert opinion only		
	Pancreatitis. Am J Gastroenterol 2012:107:1146-1150		Weak recommendation, likely to change as data becomes available		
3.	3. Wu BU, Hwang JQ, Gardner TH et al. Lactated Ringer's solution		1A/1B- Randomized trials without/with important limitations		
	reduces systemic inflammation compared with saline in patients with		Strong recommendation; likely to apply to most clinical settings		
	acute pancreatitis. Clin Gastroenterol Hepatol 2011; 9: 710 – 7.				
4.	4. Buxbaum JL, Quezada M, Da B, et al. Early Aggressive Hydration		1A/1B- Randomized trials without/with important limitations		
	Hastens Clinical Improvement in Mild	Acute Pancreatitis. Am J	Strong recommendation; likely to apply to most practice settings		
	Gastroenterol 2017; 112:797-803.				
5.	5. Alireza Shaygan-nejad, Abdol Rahim Masjedizadeh et al. Aggressive		1A/1B- Randomized trials without/with important limitations		
	hydration with Lactated Ringer's solution as the prophylactic		Strong recommendation; likely to apply to most clinical settings		
	intervention for postendoscopic retrograde cholangiopancreatography				
	pancreatitis: A randomized controlled double-blind clinical trial. Res				
	Med Sci 2015;20:838-43.				
6.	Lipinski M, Rydzewska-Rosolowska		1C- Observational studies		
	Fluid resuscitation in acute pancreatitis: Normal saline or lactated		Intermediate-strength recommendation, may change when stronger evidence		
	Ringer's solution? World J Gastroenterol. 2015 Aug 21;21(31):9367-72.		is available		

	doi: 10.3748/wjg.v21.i31.9367. PubMed PMID: 26309362; PubMed	
	Central PMCID: PMC4541388.	
7.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3- Expert opinion only
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
	Acute pancreatitis: recent advances through randomised trials. Gut.	
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub	
	2017 Aug 24. Review. PubMed PMID: 28838972	
8.	Arvanitakis M, Dumonceau JM, Albert J, et al. Endoscopic	3- Expert opinion only
	management of acute necrotizing pancreatitis: European Society of	Weak recommendation, likely to change as data becomes available
	Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary	
	guidelines. Endoscopy. 2018 Apr; 50: 524–546. doi:	
	https://doi.org/10.1055/a-0588-5365	

Care Plan Domain: INITIAL MANAGEMENT (BASELINE- 72 HRS)

Quality Indicator:

MGMT-4.3: IF a patient is diagnosed with acute pancreatitis, THEN fluid resuscitation should be titrated according to interval assessment of vital signs, urine output, BUN and hematocrit during the first 48 hours.

11150 10 11001150		
Clinical Recommendation Fluid requirements should be reas		assessed frequently within 6 hours of admission and over the next 24-48 hours.
	The goal of aggressive hydration	should be to decrease the blood urea nitrogen.
Performance Target 96.5%		
Indicator Type (Structure/Process/	Process	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients diagnosed with acute pa	ncreatitis
Rationale (i.e. How does the indicator	Maintaining perfusion of the mic	crocirculation of the pancreas is of critical importance and reassessment at
lead to desired health outcome)?	frequent intervals ensures adequa	
	Supportin	ng Literature
Source		Methodology and GRADE
1. Tenner S, Baillie J, DeWitt J et al. American College of		3- Expert opinion only
Gastroenterology Guideline: Managen	nent of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available
Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.		
2. Tenner S. Initial management of acute pancreatitis: critical issues		3- Expert opinion only
during the first 72 hours. Am J Gastroenterol 2004; 99: 2489 – 94.		Weak recommendation, likely to change as data becomes available
3. Fisher JM & Gardner T. The "Golden	Hours" of Management of Acute	3- Expert opinion only
Pancreatitis. Am J Gastroenterol 2012:107:1146-1150		Weak recommendation, likely to change as data becomes available
4. Warndorf MG, Kurtzman JT, Bartel MJ et al. Early fluid resuscitation		1C- Observational studies
reduces morbidity among patients with acute pancreatitis. Clin		Intermediate-strength recommendation, may change when stronger evidence
Gastroenterol Hepatol 2011; 9:705 -	- 9	is available
5. Gardner TB, Vege SS, Pearson RK et al. Fluid resuscitation in acute		1C- Observational studies
pancreatitis. Clin Gastroenterol Hepate	ol 2008; 6: 1070 – 6.	Intermediate-strength recommendation, may change when stronger evidence
		is available
6. Gardner TB, Vege SS, Chari ST et al.	Faster rate of initial fluid	1C- Observational studies
resuscitation in severe acute pancreation	tis diminishes in-hospital	Intermediate-strength recommendation, may change when stronger evidence
mortality. Pancreatology 2009; 9: 770	-6.	is available

7.	Wu BU, Hwang JQ, Gardner TH et al. Lactated Ringer's solution	1A/1B- Randomized trials without/with important limitations
	reduces systemic inflammation compared with saline in patients with	Strong recommendation; likely to apply to most clinical settings
	acute pancreatitis. Clin Gastroenterol Hepatol 2011; 9: 710 – 7.	
8.	Wu BU and Conwell DL. Acute Pancreatitis Part I: Approach to Early	3- Expert opinion only
	Management. Clin Gastro Gastroenterol. 2010 May; 8:410-416.	Weak recommendation, likely to change as data becomes available
9.	Wall I, Badalov N, Baradarian R et al. Decreased morbidity and	1C- Observational studies
	mortality in patients with acute pancreatitis related to aggressive	Intermediate-strength recommendation, may change when stronger evidence
	intravenous hydration. Pancreas 2011; 40: 547 – 50.	is available
10.	Buxbaum JL, Quezada M, Da B, et al. Early Aggressive Hydration	1A/1B- Randomized trials without/with important limitations
	Hastens Clinical Improvement in Mild Acute Pancreatitis. Am J	Strong recommendation; likely to apply to most clinical settings
	Gastroenterol 2017; 112:797-803.	
11.	Singh VK, Gardner TB, Papachristou GI, et al. An international	1C- Observational studies
	multicenter study of early intravenous fluid administration and outcome	Intermediate-strength recommendation, may change when stronger evidence
	in acute pancreatitis. United European Gastroenterology Journal 2017;	is available
	5 (4): 491-498.	
12.	Brown A, Orav J, Banks PA. Hemoconcentration is an early marker for	1C- Observational studies
	organ failure and necrotizing pancreatitis. Pancreas 2000; 20: 367 – 72.	Intermediate-strength recommendation, may change when stronger evidence
		is available
13.	Wu BU, Johannes RS, Sun X et al. Early changes in blood urea	1C- Observational studies
	nitrogen predict mortality in acute pancreatitis. Gastroenterology 2009;	Intermediate-strength recommendation, may change when stronger evidence
	137: 129 – 35.	is available
14.	Haydock MD, Mittal A, Wilms HR, Phillips A, Petrov MS, Windsor	1C+ Overwhelming evidence from observational studies
	JA. Fluid therapy in acute pancreatitis: anybody's guess. Ann Surg.	Strong recommendation; can apply to most practice settings in most situations
	2013 Feb;257(2):182-8. doi: 10.1097/SLA.0b013e31827773ff. Review.	
15.	Gardner TB, Olenec CA, Chertoff JD, Mackenzie TA, Robertson DJ.	1C- Observational studies
	Hemoconcentration and pancreatic necrosis: further defining the	Intermediate-strength recommendation, may change when stronger evidence
	relationship. Pancreas. 2006 Aug; 33(2):169-73. PubMed PMID:	is available
	16868483.	
16.	Lankisch PG, Mahlke R, Blum T, Bruns A, Bruns D, Maisonneuve P,	1C- Observational studies
	Lowenfels AB. Hemoconcentration: an early marker of severe and/or	Intermediate-strength recommendation, may change when stronger evidence
	necrotizing pancreatitis? A critical appraisal. Am J Gastroenterol. 2001	is available
	Jul; 96(7):2081-5. PubMed PMID: 11467635.	
17.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3- Expert opinion only
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
1	Acute pancreatitis: recent advances through randomised trials. Gut.	

2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub 2017 Aug 24. Review. PubMed PMID: 28838972	
18. Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol. 2002	3- Expert opinion only Weak recommendation, likely to change as data becomes available
Jun;97(6):1309-18. Review. PubMed PMID: 12094843.	
19. Koutroumpakis E, Wu BU, Bakker OJ, Dudekula A, Singh VK,	1C- Observational studies
Besselink MG, Yadav D, Mounzer R, van Santvoort HC, Whitcomb DC, Gooszen HG, Banks PA, Papachristou GI. Admission Hematocrit and Rise in Blood Urea Nitrogen at 24 h Outperform other Laboratory	Intermediate-strength recommendation, may change when stronger evidence is available
Markers in Predicting Persistent Organ Failure and Pancreatic Necrosis in Acute Pancreatitis: A Post Hoc Analysis of Three Large Prospective	
Databases. Am J Gastroenterol. 2015 Dec;110(12):1707-16. doi:	
10.1038/ajg.2015.370. Epub 2015 Nov 10. Erratum in: Am J	
Gastroenterol. 2016 Aug;111(8):1216. Mounzer, Rawad [added]. PubMed PMID: 26553208.	
20. Aggarwal A, Manrai M, Kochhar R. Fluid resuscitation in acute	3- Expert opinion only
pancreatitis. World J Gastroenterol. 2014 Dec 28;20(48):18092-103.	Weak recommendation, likely to change as data becomes available
doi: 10.3748/wjg.v20.i48.18092. Review. PubMed PMID: 25561779;	
PubMed Central PMCID: PMC4277949.	
21. Arvanitakis M, Dumonceau JM, Albert J, et al. Endoscopic	3- Expert opinion only
management of acute necrotizing pancreatitis: European Society of	Weak recommendation, likely to change as data becomes available
Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary	
guidelines. Endoscopy. 2018 Apr; 50: 524–546. doi:	
https://doi.org/10.1055/a-0588-5365	

Care Plan Domain: ERCP IN ACUTE PANCREATITIS

Quality Indicator:

ERCP-5.1: IF a patient has acute pancreatitis with cholangitis, THEN they should undergo ERCP with appropriate endotherapy within 24 hours of diagnosis.

with appropriate chaothers		8		
Clinical Recommendation	•	nd concurrent acute cholangitis should undergo urgent endoscopic retrograde		
	cholangiopancreatography (ERC	P) within 24 hours of admission.		
Performance Target 95%				
Indicator Type (Structure/Process/ Process, Efficiency				
Outcome)				
Indicator Level (Hospital/Patient) Patient				
Target Population Patients with acute pancreatitis a		nd cholangitis		
Rationale (i.e. How does the indicator Patients with acute pancreatitis and		nd concurrent acute cholangitis should undergo endoscopic retrograde		
lead to desired health outcome)?	cholangiopancreatography (ERC	cholangiopancreatography (ERCP) within 24 h of admission. Early intervention of cholangitis could potentially		
	limit complications and risk of m	ortality.		
Supporting Literature				
Source		Methodology and GRADE		
1. Tenner S, Baillie J, DeWitt J et al. An	nerican College of	3- Expert opinion only		
Gastroenterology Guideline: Manager	nent of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available		
Gastroenterol. 2013 Sep; 108(9):1400	-15; 1416.			
2. Tenner S. Initial management of acute	pancreatitis: critical decisions	3- Expert opinion only		
during the first 72 hours. Am J Gastroenterol 2004; 99: 2489 – 94.		Weak recommendation, likely to change as data becomes available		
3. Tarnasky P, ERCP peri-cholecystectomy. Book Chapter. ERCP: The		3- Expert opinion only		
Fundamentals, Second Edition. Edited by Peter B. Cotton and Joseph		Weak recommendation, likely to change as data becomes available		
Leung. 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley &				
Sons, Ltd.				
4. Ayub K, Imada R, Slavin J. ERCP in gallstone associated acute		1C+ Overwhelming evidence from observational studies		
pancreatitis. Cochrane Database Syst	Rev 2004: CD003630.	Strong recommendation, can apply to most practice settings in most situations		
5. Kraft M, Lerch MM. Gallstone pancreatitis: when is endoscopic		3- Expert opinion only		
retrograde cholangiopancreatography truly necessary? Curr		Weak recommendation, likely to change as data becomes available		
Gastroenterol Rep. 2003 Apr;5(2):125	5-32. Review.			
6. Attasaranya S, Fogel EL, Lehman GA	. Choledocholithiasis, ascending	3- Expert opinion only		
cholangitis, and gallstone pancreatitis.	. Med Clin North Am. 2008	Weak recommendation, likely to change as data becomes available		
Jul;92(4):925-60, x. doi: 10.1016/j.mc	ena.2008.03.001. Review.			

7.	Tse F, Yuan Y. Early routine endoscopic retrograde cholangiopancreatography strategy versus early conservative management strategy in acute gallstone pancreatitis. Cochrane Database Syst Rev. 2012 May 16;(5):CD009779. doi: 10.1002/14651858.CD009779.pub2. Review. PubMed PMID: 22592743.	1C+ Overwhelming evidence from observational studies Strong recommendation, can apply to most practice settings in most situations
8.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group Acute pancreatitis: recent advances through randomised trials. Gut. 2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub 2017 Aug 24. Review. PubMed PMID: 28838972	3- Expert opinion only Weak recommendation, likely to change as data becomes available
9.	Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology. 2018 Mar;154(4):1096-1101. doi: 10.1053/j.gastro.2018.01.032. Epub 2018 Feb 3. PubMed PMID: 29409760.	3 Expert opinion only Weak recommendation, likely to change as data becomes available
10.	Arvanitakis M, Dumonceau JM, Albert J, et al. Endoscopic management of acute necrotizing pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary guidelines. Endoscopy. 2018 Apr; 50: 524–546. doi: https://doi.org/10.1055/a-0588-5365	3- Expert opinion only Weak recommendation, likely to change as data becomes available

Quality Indicator:

ERCP-5.2: IF a patient has biliary pancreatitis and a low probability* of choledocholithiasis, THEN ERCP is not indicated.

Cli	nical Recommendation	Routine ERCP is not appropriate manifested by an elevation in the	unless there is a high suspicion of a persistent common bile duct stone, bilirubin.
Pe	rformance Target	5%	
Inc	dicator Type (Structure/Process/	Process, Appropriateness	
Ου	tcome)		
Inc	licator Level (Hospital/Patient)	Patient	
Ta	rget Population	Patients with acute biliary pancre	eatitis
Ra	tionale (i.e. How does the indicator		s with acute pancreatitis without ongoing biliary obstruction
lea	d to desired health outcome)?	*Low Probability of choledochol	lithiasis (CDL): Normal LFTs and common bile duct diameter ≤ 7mm
		Supportir	ng Literature
	Source		Methodology and GRADE
1.	Tenner S, Baillie J, DeWitt J et al. Am Gastroenterology Guideline: Managen Gastroenterol. 2013 Sep; 108(9):1400-	nent of Acute Pancreatitis. Am J	3- Expert opinion only Weak recommendation, likely to change as data becomes available
2.	Tarnasky P, ERCP peri-cholecystector Fundamentals, Second Edition. Edited Leung. 2015 John Wiley & Sons, Ltd. Sons, Ltd.	by Peter B. Cotton and Joseph	3- Expert opinion only Weak recommendation, likely to change as data becomes available
3.	Ayub K, Imada R, Slavin J. ERCP in g pancreatitis. Cochrane Database Syst l		1C+ Overwhelming evidence from observational studies Strong recommendation, can apply to most practice settings in most situations
4.	Fogel EL, Sherman S. Acute biliary parendoscopist intervene? Gastroenterolo Review		3- Expert opinion only Weak recommendation, likely to change as data becomes available
5.	Attasaranya S, Fogel EL, Lehman GA cholangitis, and gallstone pancreatitis. Jul;92(4):925-60, x. doi: 10.1016/j.mc	Med Clin North Am. 2008	3- Expert opinion only Weak recommendation, likely to change as data becomes available
6.	Arvanitakis M, Dumonceau JM, Alba management of acute necrotizing panc Gastrointestinal Endoscopy (ESGE) ev	reatitis: European Society of	3- Expert opinion only Weak recommendation, likely to change as data becomes available

guidelines. Endoscopy. 2018 Apr; 50: 524–546. doi:	
https://doi.org/10.1055/a-0588-5365	

Quality Indicator:

ERCP-5.3: IF a patient has biliary pancreatitis and has an intermediate probability* of choledocholithiasis, THEN intraoperative cholangiography should be performed during cholecystectomy or adjunctive imaging (EUS/MRCP) should be performed before discharge.

Cl	inical Recommendation	At centers where expertise for EF	RCP is low, diagnostic EUS/MRCP should be performed prior to
		cholecystectomy when there is in	termediate suspicion for choledocholithiasis in patients with acute biliary
		pancreatitis.	
Pe	rformance Target	90%	
In	dicator Type (Structure/Process/	Process	
Oı	itcome)		
In	dicator Level (Hospital/Patient)	Patient	
Ta	rget Population	Patients with acute biliary pancre	atitis
Ra	tionale (i.e. How does the indicator	When a diagnosis of choledochol	ithiasis is unclear and expertise for ERCP at a center is low, performing
lea	d to desired health outcome)?	EUS/MRCP prior to cholecystect	omy is both a reasonable and cost-effective approach.
		*Intermediate probability of CDI	L: Increased LFTs or CBD > 7 mm
		Supportin	g Literature
	Source		Methodology and GRADE
1.	Tarnasky P, ERCP peri-cholecystector	ny. Book Chapter. ERCP: The	3- Expert opinion only
	Fundamentals, Second Edition. Edited	by Peter B. Cotton and Joseph	Weak recommendation, likely to change as data becomes available
	Leung. 2015 John Wiley & Sons, Ltd.	Published 2015 by John Wiley &	
	Sons, Ltd.		
2.	Fogel EL, Sherman S. Acute biliary pa	nncreatitis: when should the	3- Expert opinion only
	endoscopist intervene? Gastroenterological	gy. 2003 Jul; 125(1):229-35.	Weak recommendation, likely to change as data becomes available
	Review		
3.	Attasaranya S, Fogel EL, Lehman GA	. Choledocholithiasis, ascending	3- Expert opinion only
	cholangitis, and gallstone pancreatitis.	Med Clin North Am. 2008	Weak recommendation, likely to change as data becomes available
	Jul;92(4):925-60, x. doi: 10.1016/j.mc	na.2008.03.001. Review.	
4.	Tse F, Yuan Y. Early routine endoscop		1C+ Overwhelming evidence from observational studies
	cholangiopancreatography strategy ver		Strong recommendation, can apply to most practice settings in most situations
	management strategy in acute gallston		
	Syst Rev. 2012 May 16;(5):CD009779		
	10.1002/14651858.CD009779.pub2. R	keview. PubMed PMID:	

22592743.	

Quality Indicator:

ERCP-5.4: IF a patient has biliary pancreatitis but is not a surgical candidate, THEN ERCP with biliary sphincterotomy and stone extraction (if applicable) should be performed before discharge.

omary spinicter otomy and	Swife exit action (if ap	pheable) should be performed before discharge.
Clinical Recommendation	ERCP with endoscopic sphincter	rotomy is a safe alternative to laparoscopic cholecystectomy to prevent further
	attacks of acute biliary pancreatit	tis in high-risk surgical patients and the elderly.
Performance Target	90%	
Indicator Type (Structure/Process/	Process, Efficiency	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	High-risk surgical patients, elder	ly patients with acute biliary pancreatitis
Rationale (i.e. How does the indicator	High-risk surgical patients and a	proportion of elderly patients with significant comorbidities are at high risk for
lead to desired health outcome)?	general anesthesia and surgery.	
	Supportin	ng Literature
Source		Methodology and GRADE
1. Fogel EL, Sherman S. Acute biliary pa	ancreatitis: when should the	3- Expert opinion only
endoscopist intervene? Gastroenterolo	ogy. 2003 Jul; 125(1):229-35.	Weak recommendation, likely to change as data becomes available
Review		
2. Bignell M, Dearing M, et al. ERCP an	nd Endoscopic Sphincterotomy	1C Observational studies
(ES): A Safe and Definitive Managem	nent of Gallstone Pancreatitis with	Intermediate-strength recommendation, may change when stronger evidence
the Gallbladder Left In Situ. J Gastroi		is available
3. Pezzilli R. Endoscopic sphincterotomy	y in acute biliary pancreatitis: A	1C Observational studies
question of anesthesiological risk. Wo		Intermediate-strength recommendation, may change when stronger evidence
Oct 15;1(1):17-20. doi: 10.4253/wjge.	v1.i1.17. PubMed PMID:	is available
21160646; PubMed Central PMCID: l	PMC2998844.	
4. Hernandez V, Pascual I, Almela P, Añ		1C Observational studies
Minguez M, Benages A. Recurrence of		Intermediate-strength recommendation, may change when stronger evidence
relationship with cholecystectomy or e	endoscopic sphincterotomy. Am J	is available
Gastroenterol. 2004 Dec;99(12):2417-	-23. PubMed PMID: 15571590	

Quality Indicator:

ERCP-5.5: IF a patient is diagnosed with biliary pancreatitis and choledocholithiasis is confirmed, THEN ductal clearance should be achieved before discharge.

	8
Clinical Recommendation	Selective postoperative ERCP should be performed for patients recovering from mild to moderate acute biliary
	pancreatitis, who have been found to have evidence of common bile duct stones on intraoperative
	cholangiogram following cholecystectomy.
Performance Target	98%
Indicator Type (Structure/Process/	Process, Efficiency
Outcome)	
Indicator Level (Hospital/Patient)	Patient
Target Population	Patients with acute biliary pancreatitis with an intraoperative cholangiogram positive for choledocholithiasis.
Rationale (i.e. How does the indicator	Selective postoperative ERCP in patients positive for choledocholithiasis on intraoperative cholangiogram is
lead to desired health outcome)?	more cost-effective than routine preoperative ERCP in patients with increased risk for common bile duct stones.
	Supporting Literature

Supporting Literature

Source	Methodology and GRADE
1. Tabone LE, Conlon M, Fernando E, Yi S, Sarker S, Fisichella PM,	1C Observational studies
Luchette FA. A practical cost-effective management strategy for	Intermediate-strength recommendation, may change when stronger evidence
gallstone pancreatitis. Am J Surg. 2013 Oct;206(4):472-7. doi:	is available
10.1016/j.amjsurg.2012.12.009. Epub 2013 Apr 28.	
2. Kuo VC, Tarnasky PR. Endoscopic management of acute biliary	3- Expert opinion only
pancreatitis. Gastrointest Endosc Clin N Am. 2013 Oct;23(4):749-68.	Weak recommendation, likely to change as data becomes available
doi: 10.1016/j.giec.2013.06.002. Review.	

Care Plan Domain: NUTRITION IN ACUTE PANCREATITIS

Quality Indicator:

NUTR-6.1: IF a patient is diagnosed with acute pancreatitis [regardless of severity], THEN enteral feeding is the preferred route of nutrition (over parenteral feeding) unless it is not tolerated or is contraindicated (i.e. bowel obstruction or paralytic ileus)

contraindicated (i.e. bowel	obstruction or paralyti	c neus)
Clinical Recommendation		teral feedings has been shown to be both more cost effective and superior to
		nting pancreatic infectious complications and sepsis related sequelae.
Indicator Type (Structure/Process/	Process, Appropriateness	
Outcome)		
Performance Target	98%	
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients diagnosed with acute par	
Rationale (i.e. How does the indicator		with NG or NJ feeding) prevents intestinal mucosal atrophy and preserves the
lead to desired health outcome)?		acterial translocation across the gut. Additionally TPN is associated with line
	associated sepsis/infections.	
	Supportin	g Literature
Source		Methodology and GRADE
1. Banks PA, Freeman ML. Practice guid	lelines in acute pancreatitis. Am J	3- Expert opinion only
Gastroenterol 2006; 101: 2379 – 400.		Weak recommendation, likely to change as data becomes available
2. Eckerwall GE, Tingstedt BB, Bergenz	aun PE, et al. Immediate oral	1A/1B- Randomized trials without/with important limitations
feeding in patients with mild acute par	creatitis is safe and may	Strong recommendation; likely to apply to most clinical settings
accelerate recovery- A randomized clin	nical study. Clin Nutr 20017 Dec;	
26(6): 754-63		
3. Jacobson BC, Vander Vliet, MB, Hugh	nes MD, et al. A prospective,	1A/1B- Randomized trials without/with important limitations
randomized trial of clear liquids versus	s low-fat solid diet as the initial	Strong recommendation; likely to apply to most clinical settings
meal in mild acute pancreatitis. Clin C	Gastroenterol Hepatol. 2007 Aug;	
5(8):946-51	•	
4. Sathiaraj E, Murthy S, Mansard MJ. C	linical trial; oral feeding with a	1A/1B- Randomized trials without/with important limitations
soft diet compared with clear liquid die		Strong recommendation; likely to apply to most clinical settings
pancreatitis. Ailment Pharmacol Ther.		
5. Moraes JM, Felga GE, Chelbi LA, et a		1A/1B- Randomized trials without/with important limitations
meal in mild acute pancreatitis is safe		Strong recommendation; likely to apply to most clinical settings
hospitalization; results from a prospect	e	
double-blind clinical trial. J Clin Gastr		
22	oemoroi. 2010 Hug, ++(1). 311-	
22		

6.	Horibe M, Nishizawa t, Suzuki H, et al. Timing of oral refeeding in	1C+ Overwhelming evidence from observational studies
	acute pancreatitis: A systematic review and meta-analysis. United	Strong recommendation; can apply to most practice settings in most situations
	European Gastroenterol J. 2016 Dec; 4(6): 725-732	
7.	Bevan MG, Asrani VM, Bharmal S, Wu LM, Windsor JA, Petrov MS.	1C+ Overwhelming evidence from observational studies
	Incidence and predictors of oral feeding intolerance in acute	Strong recommendation; can apply to most practice settings in most situations
	pancreatitis: A systematic review, meta-analysis, and meta-regression.	
	Clin Nutr. 2017 Jun; 36(3):722-729.	
8.	Oláh A, Romics L Jr. Enteral nutrition in acute pancreatitis: a review of	3- Expert opinion only
	the current evidence. World J Gastroenterol. 2014 Nov 21;	Weak recommendation, likely to change as data becomes available
	20(43):16123-31. doi: 10.3748/wjg.v20.i43.16123. Review. PubMed	
	PMID: 25473164; PubMed Central PMCID: PMC4239498.	
9.	Lariño-Noia J, Lindkvist B, Iglesias-García J, Seijo-Ríos S, Iglesias-	1A/1B- Randomized trials without/with important limitations
	Canle J, Domínguez-Muñoz JE. Early and/or immediately full caloric	Strong recommendation; likely to apply to most clinical settings
	diet versus standard refeeding in mild acute pancreatitis: a randomized	
	open-label trial. Pancreatology. 2014 May-Jun; 14(3):167-73. doi:	
	10.1016/j.pan.2014.02.008. Epub 2014 Mar 14. PubMed PMID:	
	24854611.	
10	. Chebli JM, Gaburri PD, Chebli LA. Oral refeeding in mild acute	3- Expert opinion only
	pancreatitis: an old challenge. World J Gastrointest Pathophysiol. 2011	Weak recommendation, likely to change as data becomes available
	Dec 15;2(6):100-2. doi: 10.4291/wjgp.v2.i6.100. PubMed PMID:	
	22180843; PubMed Central PMCID: PMC3240901.	
11	. Petrov MS, Kukosh MV, Emelyanov NV. A randomized controlled trial	1A/1B- Randomized trials without/with important limitations
	of enteral versus parenteral feeding in patients with predicted severe	Strong recommendation; likely to apply to most clinical settings
	acute pancreatitis shows a significant reduction in mortality and in	
	infected pancreatic complications with total enteral nutrition. Dig Surg.	
	2006; 23(5-6):336-44; discussion 344-5. Epub 2006 Dec 12.	
12	. Louie BE, Noseworthy T, Hailey D, Gramlich LM, Jacobs P, Warnock	1A/1B- Randomized trials without/with important limitations
	GL. 2004 MacLean-Mueller prize enteral or parenteral nutrition for	Strong recommendation; likely to apply to most clinical settings
	severe pancreatitis: a randomized controlled trial and health technology	
	assessment. Can J Surg. 2005 Aug; 48(4):298-306. PubMed PMID:	
	16149365	
13	. Casas M, Mora J, Fort E, Aracil C, Busquets D, Galter S, Jáuregui CE,	1A/1B- Randomized trials without/with important limitations
	Ayala E, Cardona D, Gich I, Farré A. [Total enteral nutrition vs. total	Strong recommendation; likely to apply to most clinical settings
	parenteral nutrition in patients with severe acute pancreatitis]. Rev Esp	
	Enferm Dig. 2007 May; 99(5):264-9.	
14	. Gupta R, Patel K, Calder PC, Yaqoob P, Primrose JN, Johnson CD. A	1A/1B- Randomized trials without/with important limitations
	randomised clinical trial to assess the effect of total enteral and total	Strong recommendation; likely to apply to most clinical settings
	parenteral nutritional support on metabolic, inflammatory and oxidative	

markers in patients with predicted severe acute pancreatitis (APACHE	
 II > or =6). Pancreatology. 2003; 3(5):406-13. Epub 2003 Sep 24. 15. Yi F, Ge L, Zhao J, Lei Y, Zhou F, Chen Z, Zhu Y, Xia B. Meta-analysis: total parenteral nutrition versus total enteral nutrition in predicted severe acute pancreatitis. Intern Med. 2012; 51(6):523-30. Epub 2012 Mar 15. 	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
16. Wu XM, Ji KQ, Wang HY, Li GF, Zang B, Chen WM. Total enteral nutrition in prevention of pancreatic necrotic infection in severe acute pancreatitis. Pancreas. 2010 Mar; 39(2):248-51. doi: 10.1097/MPA.0b013e3181bd6370.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
17. Abou-Assi S, Craig K, O'Keefe SJ. Hypocaloric jejunal feeding is better than total parenteral nutrition in acute pancreatitis: results of a randomized comparative study. Am J Gastroenterol. 2002 Sep; 97(9):2255-62.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
18. Li JY, Yu T, Chen GC, Yuan YH, Zhong W, Zhao LN, Chen QK. Enteral nutrition within 48 hours of admission improves clinical outcomes of acute pancreatitis by reducing complications: a meta-analysis. PLoS One. 2013 Jun 6;8(6):e64926. doi: 10.1371/journal.pone.0064926. Print 2013.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
19. Doley RP, Yadav TD, Wig JD, Kochhar R, Singh G, Bharathy KG, Kudari A, Gupta R, Gupta V, Poornachandra KS, Dutta U, Vaishnavi C. Enteral nutrition in severe acute pancreatitis. JOP. 2009 Mar 9; 10(2):157-62.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
20. Oláh A, Pardavi G, Belágyi T, Nagy A, Issekutz A, Mohamed GE. Early nasojejunal feeding in acute pancreatitis is associated with a lower complication rate. Nutrition. 2002 Mar; 18(3):259-62.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
21. McClave SA, Greene LM, Snider HL, Makk LJ, Cheadle WG, Owens NA, Dukes LG, Goldsmith LJ. Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitis. JPEN J Parenter Enteral Nutr. 1997 Jan-Feb; 21(1):14-20.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
22. Petrov MS, Whelan K. Comparison of complications attributable to enteral and parenteral nutrition in predicted severe acute pancreatitis: a systematic review and meta-analysis. Br J Nutr. 2010 May;103(9):1287-95. doi: 10.1017/S0007114510000887. Epub 2010 Apr 7. Review.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
23. Quan H, Wang X, Guo C. A meta-analysis of enteral nutrition and total parenteral nutrition in patients with acute pancreatitis. Gastroenterol Res Pract. 2011; 2011:698248. doi: 10.1155/2011/698248. Epub 2011	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations

Jun 2. PubMed PMID: 21687619	
24. Pan LL, Li J, Shamoon M, Bhatia M, Sun J. Recent Advances on Nutrition in Treatment of Acute Pancreatitis. Front Immunol. 2017 Jun 30; 8:762. doi: 10.3389/fimmu.2017.00762. eCollection 2017. Review.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
25. Gramlich L, Kichian K, Pinilla J, Rodych NJ, Dhaliwal R, Heyland DK. Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature. Nutrition. 2004 Oct;20(10):843-8. Review.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
26. Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics Committee.; AGA Institute Governing Board AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007 May;132(5):2022-44. Review. PubMed PMID: 17484894.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
27. van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group Acute pancreatitis: recent advances through randomised trials. Gut. 2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub 2017 Aug 24. Review. PubMed PMID: 28838972	3- Expert opinion only Weak recommendation, likely to change as data becomes available
28. O'Keefe SJ, Broderick T, Turner M, Stevens S, O'Keefe JS. Nutrition in the management of necrotizing pancreatitis. Clin Gastroenterol Hepatol. 2003 Jul;1(4):315-21. PubMed PMID: 15017674.	
29. Rinninella E, Annetta MG, Serricchio ML, Dal Lago AA, Miggiano GA, Mele MC. Nutritional support in acute pancreatitis: from physiopathology to practice. An evidence-based approach. Eur Rev Med Pharmacol Sci. 2017 Jan;21(2):421-432. Review. PubMed PMID: 28165542.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
30. Meier R, Ockenga J, Pertkiewicz M, Pap A, Milinic N, Macfie J; DGEM (German Society for Nutritional Medicine)., Löser C, Keim V; ESPEN (European Society for Parenteral and Enteral Nutrition) ESPEN Guidelines on Enteral Nutrition: Pancreas. Clin Nutr. 2006 Apr;25(2):275-84. Epub 2006 May 6. PubMed PMID: 16678943.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
31. Mentula P, Leppäniemi A. Position paper: timely interventions in severe acute pancreatitis are crucial for survival. World J Emerg Surg. 2014 Feb 10;9(1):15. doi: 10.1186/1749-7922-9-15. PubMed PMID: 24512891; PubMed Central PMCID: PMC3926684.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
32. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN; American Gastroenterological Association Institute Clinical	3 Expert opinion only Weak recommendation, likely to change as data becomes available

Guid	elines Committee American Gastroenterological
Asso	ciation Institute Guideline on Initial Management of Acute
Panc	reatitis. Gastroenterology. 2018 Mar;154(4):1096-1101. doi:
10.10	053/j.gastro.2018.01.032. Epub 2018 Feb 3. PubMed PMID:
2940	9760.

Care Plan Domain: NUTRITION IN ACUTE PANCREATITIS

Quality Indicator:

NUTR-6.2: IF a patient is diagnosed with acute pancreatitis, THEN the preferred choice of enteral feeding is a low-fat solid diet as tolerated.

recuing is a low-lat solid diet as tolerated.		
		et should be started immediately once a patient's symptoms have
	-	ney can tolerate oral intake. Initiation of a low fat, solid diet is as safe
and effective as starting clear l		liquids.
Performance Target	90%	
Indicator Type (Structure/Process/	Process, Appropriateness	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients diagnosed with acute par	
Rationale (i.e. How does the indicator	<u> </u>	eding with a low fat, solid diet may accelerate recovery without increased risk
lead to desired health outcome)?		(eg pain with re-feeding), and may result in shorter length of hospitalization.
	Supportin	g Literature
Source		Methodology and GRADE
1. Eckerwall GE, Tingstedt BB, Bergenz		1A/1B- Randomized trials without/with important limitations
feeding in patients with mild acute par	_	Strong recommendation; likely to apply to most clinical settings
accelerate recovery- A randomized clinical study. Clin Nutr 20017 Dec		
; 26(6): 754-63		
2. Jacobson BC, Vander Vliet, MB, Hughes MD, et al. A prospective,		1A/1B- Randomized trials without/with important limitations
randomized trial of clear liquids versus		Strong recommendation; likely to apply to most clinical settings
meal in mild acute pancreatitis. Clin Gastroenterol Hepatol. 2007 Aug;		
5(8):946-51		
3. Sathiaraj E, Murthy S, Mansard MJ. C	•	1A/1B- Randomized trials without/with important limitations
soft diet compared with clear liquid die	et as initial meal in mild acute	Strong recommendation; likely to apply to most clinical settings
pancreatitis. Ailment Pharmacol Ther.	2008 Sep 15; 28(6):777-81	
4. Moraes JM, Felga GE, Chelbi LA, et a	d. A full solid diet as the initial	1A/1B- Randomized trials without/with important limitations
meal in mild acute pancreatitis is safe	and result in a shorter length of	Strong recommendation; likely to apply to most clinical settings
hospitalization; results from a prospect	tive, randomized, controlled,	
double-blind clinical trial. J Clin Gastr		
22	-	
5. Horibe M, Nishizawa t, Suzuki H, et a	l. Timing of oral refeeding in	1C+ Overwhelming evidence from observational studies
acute pancreatitis: A systematic review		Strong recommendation; can apply to most practice settings in most situations
European Gastroenterol J. 2016 Dec; 4	· ·	
	<u> </u>	

6.	Bevan MG, Asrani VM, Bharmal S, Wu LM, Windsor JA, Petrov MS.	1C+ Overwhelming evidence from observational studies
	Incidence and predictors of oral feeding intolerance in acute	Strong recommendation; can apply to most practice settings in most situations
	pancreatitis: A systematic review, meta-analysis, and meta-regression.	
	Clin Nutr. 2017 Jun; 36(3):722-729.	
7.	Oláh A, Romics L Jr. Enteral nutrition in acute pancreatitis: a review of	3- Expert opinion only
	the current evidence. World J Gastroenterol. 2014 Nov 21;	Weak recommendation, likely to change as data becomes available e
	20(43):16123-31. doi: 10.3748/wjg.v20.i43.16123. Review. PubMed	
	PMID: 25473164; PubMed Central PMCID: PMC4239498.	
8.	Lariño-Noia J, Lindkvist B, Iglesias-García J, Seijo-Ríos S, Iglesias-	1A/1B- Randomized trials without/with important limitations
	Canle J, Domínguez-Muñoz JE. Early and/or immediately full caloric	Strong recommendation; likely to apply to most clinical settings
	diet versus standard refeeding in mild acute pancreatitis: a randomized	
	open-label trial. Pancreatology. 2014 May-Jun; 14(3):167-73. doi:	
	10.1016/j.pan.2014.02.008. Epub 2014 Mar 14. PubMed PMID:	
	24854611.	
9.	Chebli JM, Gaburri PD, Chebli LA. Oral refeeding in mild acute	3- Expert opinion only
	pancreatitis: an old challenge. World J Gastrointest Pathophysiol. 2011	Weak recommendation, likely to change as data becomes available
	Dec 15;2(6):100-2. doi: 10.4291/wjgp.v2.i6.100. PubMed PMID:	
	22180843; PubMed Central PMCID: PMC3240901.	

Care Plan Domain: NUTRITION IN ACUTE PANCREATITIS

Quality Indicator:

NUTR-6.3: IF a patient with acute pancreatitis cannot tolerate oral feeding within 72 hours then either nasogastric or nasojejunal assisted enteral feeding should be initiated.

ettilet hasogastric of hasojejuhar assisted enteral feeding should be initiated.		
		pancreatitis, early enteral nutrition started within 48 hours, has been associated
		e infectious complications, organ failure, mortality, and length of stay. Enteral
feeding via NG route is as safe at		nd effective as NJ feeding.
Performance Target	90%	
Indicator Type (Structure/Process/	Process, Appropriateness	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population		nable to tolerate oral feeding in 24-48 hours.
Rationale (i.e. How does the indicator	`	with NG or NJ feeding) prevents intestinal mucosal atrophy and preserves the
lead to desired health outcome)?		acterial translocation across the gut. Furthermore, the data shows there is no
	significant difference in rates of mortality, infectious related complications, pain associated with feeding or LOS	
	between the two routes of enteral	
g	Supportin	g Literature
Source 1. Banks PA, Freeman ML. Practice guid	Jolinas in cauta managatitis. Am I	Methodology and GRADE
Gastroenterol 2006; 101: 2379 – 400.	iennes in acute pancreatus. Am J	3- Expert opinion only Weak recommendation, likely to change as data becomes available
·	Li CE Zana D. Whan to	1C- Observational studies
2. Wu XM, Liao YW, Wang HY, Ji KQ,		Intermediate-strength recommendation, may change when stronger evidence
initialize enteral nutrition in patients v		is available
retrospective review in a single institu	- · · · · · · · · · · · · · · · · · · ·	is available
Pancreas. 2015 Apr;44(3):507-11. doi		
10.1097/MPA.0000000000000293. Pt		
Apr;44(3):507-11. doi: 10.1097/MPA.0000000000000293. PubMed		
DV(ID 0570000		
PMID: 25723878.	XXX A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	14/ID D 1 1 14 1 21 4/ 21 1 4 4 2 2
3. Petrov MS, Kukosh MV, Emelyanov l		1A/1B- Randomized trials without/with important limitations
3. Petrov MS, Kukosh MV, Emelyanov of enteral versus parenteral feeding in	patients with predicted severe	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
3. Petrov MS, Kukosh MV, Emelyanov of enteral versus parenteral feeding in acute pancreatitis shows a significant	patients with predicted severe reduction in mortality and in	_
3. Petrov MS, Kukosh MV, Emelyanov of enteral versus parenteral feeding in acute pancreatitis shows a significant infected pancreatic complications with	patients with predicted severe reduction in mortality and in a total enteral nutrition. Dig Surg.	
3. Petrov MS, Kukosh MV, Emelyanov lof enteral versus parenteral feeding in acute pancreatitis shows a significant infected pancreatic complications with 2006; 23(5-6):336-44; discussion 344-	patients with predicted severe reduction in mortality and in a total enteral nutrition. Dig Surg. 5. Epub 2006 Dec 12.	Strong recommendation; likely to apply to most clinical settings
 Petrov MS, Kukosh MV, Emelyanov I of enteral versus parenteral feeding in acute pancreatitis shows a significant infected pancreatic complications with 2006; 23(5-6):336-44; discussion 344-4. Louie BE, Noseworthy T, Hailey D, C 	patients with predicted severe reduction in mortality and in a total enteral nutrition. Dig Surg. 5. Epub 2006 Dec 12. Framlich LM, Jacobs P, Warnock	Strong recommendation; likely to apply to most clinical settings 1A/1B- Randomized trials without/with important limitations
3. Petrov MS, Kukosh MV, Emelyanov lof enteral versus parenteral feeding in acute pancreatitis shows a significant infected pancreatic complications with 2006; 23(5-6):336-44; discussion 344-	patients with predicted severe reduction in mortality and in a total enteral nutrition. Dig Surg. 5. Epub 2006 Dec 12. Framlich LM, Jacobs P, Warnock eral or parenteral nutrition for	Strong recommendation; likely to apply to most clinical settings

	assessment. Can J Surg. 2005 Aug; 48(4):298-306. PubMed PMID: 16149365	
5.	Casas M, Mora J, Fort E, Aracil C, Busquets D, Galter S, Jáuregui CE, Ayala E, Cardona D, Gich I, Farré A. [Total enteral nutrition vs. total parenteral nutrition in patients with severe acute pancreatitis]. Rev Esp Enferm Dig. 2007 May; 99(5):264-9.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
6.	Gupta R, Patel K, Calder PC, Yaqoob P, Primrose JN, Johnson CD. A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II > or =6). Pancreatology. 2003; 3(5):406-13. Epub 2003 Sep 24.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
7.	Yi F, Ge L, Zhao J, Lei Y, Zhou F, Chen Z, Zhu Y, Xia B. Meta-analysis: total parenteral nutrition versus total enteral nutrition in predicted severe acute pancreatitis. Intern Med. 2012; 51(6):523-30. Epub 2012 Mar 15.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
8.	Wu XM, Ji KQ, Wang HY, Li GF, Zang B, Chen WM. Total enteral nutrition in prevention of pancreatic necrotic infection in severe acute pancreatitis. Pancreas. 2010 Mar; 39(2):248-51. doi: 10.1097/MPA.0b013e3181bd6370.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
9.	Krishnan K. Nutritional management of acute pancreatitis. Curr Opin Gastroenterol. 2017 Mar;33(2):102-106. doi: 10.1097/MOG.0000000000000340. Review. PubMed PMID: 28141617.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
10.	Chang Y, Fu H, Xiao Y, Liu J. Nasogastric or nasojejunal feeding in predicted severe acute pancreatitis: a meta-analysis. Critical Care. 2013;17(3):R118. doi:10.1186/cc12790.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
11.	Zhu Y, Yin H, Zhang R, Ye X, Wei J. Nasogastric Nutrition versus Nasojejunal Nutrition in Patients with Severe Acute Pancreatitis: A Meta-Analysis of Randomized Controlled Trials. Gastroenterol Res Pract. 2016;2016:6430632. doi: 10.1155/2016/6430632. Epub 2016 Jun 2. PubMed PMID: 27340401; PubMed Central PMCID: PMC4909901.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
12.	Márta K, Farkas N, Szabó I, Illés A, Vincze Á, Pár G, Sarlós P, Bajor J, Szűcs Á, Czimmer J, Mosztbacher D, Párniczky A, Szemes K, Pécsi D, Hegyi P. Meta-Analysis of Early Nutrition: The Benefits of Enteral Feeding Compared to a Nil Per Os Diet Not Only in Severe, but Also in Mild and Moderate Acute Pancreatitis. Int J Mol Sci. 2016 Oct 20; 17(10). pii: E1691. PubMed PMID: 27775609; PubMed Central PMCID: PMC5085723.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations

13. Abou-Assi S, Craig K, O'Keefe SJ. Hypocaloric jejunal feeding is	1A/1B- Randomized trials without/with important limitations
better than total parenteral nutrition in acute pancreatitis: results of a	Strong recommendation; likely to apply to most clinical settings
randomized comparative study. Am J Gastroenterol. 2002	
Sep;97(9):2255-62. PubMed PMID: 12358242.	
14. Singh N, Sharma B, Sharma M, Sachdev V, Bhardwaj P, Mani K, Joshi	1A/1B- Randomized trials without/with important limitations
YK, Saraya A. Evaluation of early enteral feeding through nasogastric	Strong recommendation; likely to apply to most clinical settings
and nasojejunal tube in severe acute pancreatitis: a noninferiority	
randomized controlled trial. Pancreas. 2012 Jan;41(1):153-9. doi:	
10.1097/MPA.0b013e318221c4a8. PubMed PMID: 21775915.	
15. Li JY, Yu T, Chen GC, Yuan YH, Zhong W, Zhao LN, Chen QK.	1C+ Overwhelming evidence from observational studies
Enteral nutrition within 48 hours of admission improves clinical	Strong recommendation; can apply to most practice settings in most situations
outcomes of acute pancreatitis by reducing complications: a meta-	
analysis. PLoS One. 2013 Jun 6;8(6):e64926. doi:	
10.1371/journal.pone.0064926. Print 2013.	
16. Doley RP, Yadav TD, Wig JD, Kochhar R, Singh G, Bharathy KG,	1A/1B- Randomized trials without/with important limitations
Kudari A, Gupta R, Gupta V, Poornachandra KS, Dutta U, Vaishnavi	Strong recommendation; likely to apply to most clinical settings
C. Enteral nutrition in severe acute pancreatitis. JOP. 2009 Mar 9;	
10(2):157-62.	
17. Bakker OJ, van Brunschot S, van Santvoort HC, et al. Early versus on-	1A/1B- Randomized trials without/with important limitations
demand nasoenteric tube feeding in acute pancreatitis. N Engl J Med.	Strong recommendation; likely to apply to most clinical settings
2014 Nov 20;371(21):1983-93. doi: 10.1056/NEJMoa1404393.	
PubMed PMID: 25409371.	
18. Vaughn VM, Shuster D, Rogers MAM, Mann J, Conte ML, Saint S,	1C+ Overwhelming evidence from observational studies
Chopra V. Early Versus Delayed Feeding in Patients With Acute	Strong recommendation; can apply to most practice settings in most situations
Pancreatitis: A Systematic Review. Ann Intern Med. 2017 Jun	
20;166(12):883-892. doi: 10.7326/M16-2533. Epub 2017 May 16.	
Review. PubMed PMID: 28505667.	
19. Oláh A, Pardavi G, Belágyi T, Nagy A, Issekutz A, Mohamed GE.	1A/1B- Randomized trials without/with important limitations
Early nasojejunal feeding in acute pancreatitis is associated with a	Strong recommendation; likely to apply to most clinical settings
lower complication rate. Nutrition. 2002 Mar; 18(3):259-62.	
20. Petrov MS, McIlroy K, Grayson L, Phillips AR, Windsor JA. Early	1A/1B- Randomized trials without/with important limitations
nasogastric tube feeding versus nil per os in mild to moderate acute	Strong recommendation; likely to apply to most clinical settings
pancreatitis: a randomized controlled trial. Clin Nutr. 2013 Oct;	
32(5):697-703. doi: 10.1016/j.clnu.2012.12.011. Epub 2012 Dec 31.	
PubMed PMID: 23340042.	
21. Kumar A, Singh N, Prakash S, Saraya A, Joshi YK. Early enteral	1A/1B- Randomized trials without/with important limitations
nutrition in severe acute pancreatitis: a prospective randomized	Strong recommendation; likely to apply to most clinical settings
controlled trial comparing nasojejunal and nasogastric routes. J Clin	

Gastroenterol. 2006 May-Jun;40(5):431-4. PubMed PMID: 16721226.	
22. McClave SA, Greene LM, Snider HL, Makk LJ, Cheadle WG, Owens NA, Dukes LG, Goldsmith LJ. Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitis. JPEN J Parenter Enteral Nutr. 1997 Jan-Feb; 21(1):14-20.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
23. Petrov MS, Whelan K. Comparison of complications attributable to enteral and parenteral nutrition in predicted severe acute pancreatitis: a systematic review and meta-analysis. Br J Nutr. 2010 May;103(9):1287-95. doi: 10.1017/S0007114510000887. Epub 2010 Apr 7. Review.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
24. Eatock FC, Chong P, Menezes N, Murray L, McKay CJ, Carter CR, Imrie CW. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. Am J Gastroenterol. 2005 Feb;100(2):432-9. PubMed PMID: 15667504.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
25. Quan H, Wang X, Guo C. A meta-analysis of enteral nutrition and total parenteral nutrition in patients with acute pancreatitis. Gastroenterol Res Pract. 2011; 2011:698248. doi: 10.1155/2011/698248. Epub 2011 Jun 2. PubMed PMID: 21687619	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
26. Pan LL, Li J, Shamoon M, Bhatia M, Sun J. Recent Advances on Nutrition in Treatment of Acute Pancreatitis. Front Immunol. 2017 Jun 30; 8:762. doi: 10.3389/fimmu.2017.00762. eCollection 2017. Review.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
27. Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics Committee.; AGA Institute Governing Board AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007 May;132(5):2022-44. Review. PubMed PMID: 17484894.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
28. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN; American Gastroenterological Association Institute Clinical Guidelines Committee American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology. 2018 Mar;154(4):1096-1101. doi: 10.1053/j.gastro.2018.01.032. Epub 2018 Feb 3. PubMed PMID: 29409760.	3 Expert opinion only Weak recommendation, likely to change as data becomes available
29. Arvanitakis M, Dumonceau JM, Albert J, et al. Endoscopic management of acute necrotizing pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary guidelines. Endoscopy. 2018 Apr; 50: 524–546.	3- Expert opinion only Weak recommendation, likely to change as data becomes available

1 1 1 //1 1 //0.1055/ 0.500 52.65	7
doi: https://doi.org/10.1055/a-0588-5365	

Quality Indicator:

PHAR-7.1: IF a patient is diagnosed with acute pancreatitis, THEN severity of pain should be assessed and managed according to institutional guidelines.

assessed and managed according to institutional guidennes.		3	
Clinical Recommendation		ving pain management practice involve education about pain assessment and	
	treatment combined with methods designed to change the institutional culture and practice of pain management.		
Adequate control of pain is imposite are usually needed.		rtant for appropriate management of acute pancreatitis and parenteral analgesic	
Performance Target 95%			
Indicator Type (Structure/Process/ Process, Appropriateness			
Outcome)			
Indicator Level (Hospital/Patient)	Patient		
Target Population	Patients with acute pancreatitis		
Rationale (i.e. How does the indicator		acute pancreatitis and its relief is a clinical priority. A critical step to providing	
lead to desired health outcome)?	good pain management is pain assessment. Inadequately managed pain can lead to adverse physical and		
	1 1 1	or individual patients and their families.	
Supporting Literature			
Source		Methodology and GRADE	
1. Weissman DE, Griffie J, Muchka S,	Matson S. Building an	3- Expert opinion only	
institutional commitment to pain man	nagement in long-term care	Weak recommendation, likely to change as data becomes available	
facilities. J Pain Symptom Manage. 2	2000 Jul;20(1):35-43. PubMed		
PMID: 10946167.			
2. Cohen MZ, Easley MK, Ellis C, Hug		3- Expert opinion only	
Rude M, Taft E, Westbrooks JB; JCAHO Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain		Weak recommendation, likely to change as data becomes available	
-			
Symptom Manage. 2003 Jun;25(6):5	19-27. PubMed PMID: 12782432.		
Symptom Manage. 2003 Jun;25(6):5 3. Wells N, Pasero C, McCaffery M. In	19-27. PubMed PMID: 12782432. proving the Quality of Care	3- Expert opinion only	
Symptom Manage. 2003 Jun;25(6):5Wells N, Pasero C, McCaffery M. In Through Pain Assessment and Manage.	19-27. PubMed PMID: 12782432. approving the Quality of Care gement. In: Hughes RG, editor.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
 Symptom Manage. 2003 Jun;25(6):5 Wells N, Pasero C, McCaffery M. In Through Pain Assessment and Manage Patient Safety and Quality: An Evide 	19-27. PubMed PMID: 12782432. proving the Quality of Care gement. In: Hughes RG, editor. cnce-Based Handbook for Nurses.	= = = = =	
Symptom Manage. 2003 Jun;25(6):5 3. Wells N, Pasero C, McCaffery M. In Through Pain Assessment and Manage.	19-27. PubMed PMID: 12782432. approving the Quality of Care gement. In: Hughes RG, editor. ence-Based Handbook for Nurses. are Research and Quality (US);		

Quality Indicator:

PHAR-7.2: IF a patient is diagnosed with biliary pancreatitis and has evidence of cholangitis, THEN they should be started on appropriate antibiotics.

they should be started on a	ppropriate antibiotics.	
Clinical Recommendation	Antibiotics should be given for a	n extrapancreatic infection, such as cholangitis, catheter-acquired infections,
	bacteremia, urinary tract infection	ns, and pneumonia.
Performance Target 99%		
Indicator Type (Structure/Process/	Process	
Outcome)		
Indicator Level (Hospital/Patient) Patient		
Target Population	Patients with acute pancreatitis at	nd evidence of cholangitis
Rationale (i.e. How does the indicator	Extrapancreatic infections are a r	najor cause of morbidity and mortality in patients with acute pancreatitis
lead to desired health outcome)?		
	Supportin	g Literature
Source		Methodology and GRADE
1. Tenner S, Baillie J, DeWitt J et al. A	merican College of	3- Expert opinion only
Gastroenterology Guideline: Manage		Weak recommendation, likely to change as data becomes available
Gastroenterol. 2013 Sep; 108(9):140	0-15; 1416.	
2. Wu BU and Conwell DL. Acute Pane	creatitis Part I: Approach to Early	3- Expert opinion only
Management. Clin Gastro Gastroenterol. 2010 May; 8:410-416.		Weak recommendation, likely to change as data becomes available
3. Bakker OJ, Issa Y, van Santvoort HO	C, et al. Treatment options for	3- Expert opinion only
acute pancreatitis. Nat Rev Gastroent	terol Hepatol 11, 462-469 (2014).	Weak recommendation, likely to change as data becomes available
4. Working Party of the British Society	of Gastroenterology.; Association	3- Expert opinion only
of Surgeons of Great Britain and Irel	and.; Pancreatic Society of Great	Weak recommendation, likely to change as data becomes available
Britain and Ireland.; Association of U	Jpper GI Surgeons of Great	
Britain and Ireland UK guidelines for	or the management of acute	
pancreatitis. Gut. 2005 May;54 Supp	l 3:iii1-9. PubMed PMID:	
15831893; PubMed Central PMCID:	PMC1867800.	
5. Mayerle J, Simon P, Lerch MM. Med	dical treatment of acute	3- Expert opinion only
pancreatitis. Gastroenterol Clin N Ar	m 33 (2004) 855–869	Weak recommendation, likely to change as data becomes available
6. Adler DG, Chari ST, Dahl TJ et al. C	Conservative management of	2C- Observational studies
infected necrosis complicating severe	e acute pancreatitis. Am J	Very weak recommendation, alternative approaches are likely to be better
Gastroenterol 2003; 98: 98 – 103.		under some circumstances

7.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group
	Acute pancreatitis: recent advances through randomised trials. Gut.
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub
	2017 Aug 24. Review. PubMed PMID: 28838972

3- Expert opinion onlyWeak recommendation, likely to change as data becomes available

Quality Indicator:

PHAR-7.3: IF a patient is diagnosed with acute pancreatitis, THEN prophylactic antibiotics should not be prescribed.

not be preseribed.		
Clinical Recommendation		piotics in patients with severe acute pancreatitis is not recommended. Prevention
	of fungal infections in patients with acute pancreatitis is also not recommended.	
Performance Target 10%		
Indicator Type (Structure/Process/	Process, Appropriateness	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients with acute pancreatitis w	vith no clinical evidence of infection
Rationale (i.e. How does the indicator		gence of fungal superinfections with the use of prophylactic broad-spectrum
lead to desired health outcome)?		f fungal infections in patients with acute pancreatitis has not been shown to be
	beneficial.	
Supporting Literature		ig Literature
Source		Methodology and GRADE
1. Tenner S, Baillie J, DeWitt J et al. A	merican College of	3- Expert opinion only
Gastroenterology Guideline: Management of Acute Pancreatitis. Am J		Weak recommendation, likely to change as data becomes available
Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.		
2. Wu BU and Conwell DL. Acute Pane		3- Expert opinion only
Management. Clin Gastro Gastroenterol. 2010 May; 8:410-416.		Weak recommendation, likely to change as data becomes available
3. Bakker OJ, Issa Y, van Santvoort HC	C, et al. Treatment options for	3- Expert opinion only
acute pancreatitis. Nat Rev Gastroent	terol Hepatol 11, 462-469 (2014).	Weak recommendation, likely to change as data becomes available
4. Working Party of the British Society		3- Expert opinion only
of Surgeons of Great Britain and Irel	· ·	Weak recommendation, likely to change as data becomes available
Britain and Ireland.; Association of U		
Britain and Ireland UK guidelines for		
pancreatitis. Gut. 2005 May;54 Supp		
15831893; PubMed Central PMCID:		
5. Mayerle J, Simon P, Lerch MM. Med		3- Expert opinion only
pancreatitis. Gastroenterol Clin N Ar		Weak recommendation, likely to change as data becomes available
6. Adler DG, Chari ST, Dahl TJ et al. Conservative management of		2C- Observational studies

	infected necrosis complicating severe acute pancreatitis. Am J	Very weak recommendation, alternative approaches are likely to be better
	Gastroenterol 2003; 98: 98 – 103.	under some circumstances
7.	De Vries A, Besselink MG, Buskens E et al. Randomized controlled	1C+ Overwhelming evidence from observational studies
	trialsof antibiotic prophylaxis in severe acute pancreatitis: relationship	Strong recommendation; can apply to most practice settings in most situations
	between methodologic quality and outcome. Pancreatology 2007; 7:	
	531 – 8.	
8.	Isenmann R, Runzi M, Kron M et al. Prophylactic antibiotic treatment	1A/1B- Randomized trials without/with important limitations
	in patients with predicted severe acute pancreatitis: a placebo-	Strong recommendation; likely to apply to most clinical settings
	controlled, double-blind trial. Gastroenterology 2004; 126: 997 – 1004	
9.	Jiang K, Huang W, Yang XN et al. Present and future of prophylactic	1C- Observational studies
	antibiotics for severe acute pancreatitis. World J Gastroenterol 2012;	Intermediate-strength recommendation, may change when stronger evidence
	18:279 – 84.	is available
10.	Jafri NS, Mahid SS, Idstein SR et al. Antibiotic prophylaxis is not	1C+ Overwhelming evidence from observational studies
	protective in severe acute pancreatitis: a systematic review and meta-	Strong recommendation; can apply to most practice settings in most situations
	analysis . Am J Surg 2009; 197: 806 – 13.	
11.	Guru Trikudanathan et al. Intra-Abdominal Fungal Infections	3- Expert opinion only
	Complicating Acute Pancreatitis: A Review. Am J Gastroenterol.	Weak recommendation, likely to change as data becomes available
	2011; 106: 1188 – 1192	
12.	Villatoro E, Mulla M, Larvin M. Antibiotic therapy for prophylaxis	1C+ Overwhelming evidence from observational studies
	against infection of pancreatic necrosis in acute pancreatitis. Cochrane	Strong recommendation; can apply to most practice settings in most situations
	Database of Systematic Reviews 2010, Issue 5. Art.No.: CD002941.	
	DOI: 10.1002/14651858.CD002941.pub3.	
13.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3- Expert opinion only
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
	Acute pancreatitis: recent advances through randomised trials. Gut.	
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub	
	2017 Aug 24. Review. PubMed PMID: 28838972	
14.	Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN;	3 Expert opinion only
	American Gastroenterological Association Institute Clinical	Weak recommendation, likely to change as data becomes available
	Guidelines Committee. American Gastroenterological Association	
	Institute Guideline on Initial Management of Acute Pancreatitis.	
	Gastroenterology. 2018 Mar;154(4):1096-1101. doi:	
	10.1053/j.gastro.2018.01.032. Epub 2018 Feb 3. PubMed PMID:	
	29409760.	
15.	Arvanitakis M, Dumonceau JM, Albert J, et al. Endoscopic	3- Expert opinion only
	management of acute necrotizing pancreatitis: European Society of	Weak recommendation, likely to change as data becomes available
	Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary	

guidelines. Endoscopy. 2018 Apr; 50: 524–546. doi:	
https://doi.org/10.1055/a-0588-5365	

Quality Indicator:

PHAR-7.4: IF a patient is predicted to have severe acute pancreatitis, THEN probiotic agents should not be prescribed.

not be prescribed.			
Cli	Clinical Recommendation Probiotics should not be given in		patients with predicted severe acute pancreatitis.
Per	Performance Target 2%		
Ind	Indicator Type (Structure/Process/ Process, Appropriateness		
Ou	tcome)		
Ind	icator Level (Hospital/Patient)	Patient	
Tai	get Population	Patients predicted to have severe	-
Rat	ionale (i.e. How does the indicator	A very well-conducted randomize	ed control clinical trial demonstrated increased mortality associated with
lea	d to desired health outcome)?	routine use of probiotics	
		Supportin	ng Literature
	Source		Methodology and GRADE
1.	Tenner S, Baillie J, DeWitt J et al. Ar	merican College of	3- Expert opinion only
	Gastroenterology Guideline: Manage	ment of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available
	Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.		
2.	Besselink MG, van Santvoort HC, Bu	iskens E et al. Probiotic	1A/1B- Randomized trials without/with important limitations
	prophylaxis in predicted severe acute pancreatitis: a rando		Strong recommendation; likely to apply to most clinical settings
	double-blind, placebo-controlled trial. Lancet 2008; 371: 651 – 9.		
3.	Sun S, Yang K, He X et al. Langenbe	_	1C+ Overwhelming evidence from observational studies
	severe acute pancreatitis: a metaanalysis . Arch Surg 2009; 394: 171 –		Strong recommendation; can apply to most practice settings in most situations
	7.		
4.	van Dijk SM, Hallensleben NDL, van		3- Expert opinion only
	Goor H, Bruno MJ, Besselink MG; D	• •	Weak recommendation, likely to change as data becomes available
	Acute pancreatitis: recent advances through randomised trials. Gut.		
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub		
	2017 Aug 24. Review. PubMed PMII		2 E
5.	Arvanitakis M, Dumonceau JM, Alb	•	3- Expert opinion only Weak recommendation, likely to change as data becomes available
	management of acute necrotizing pan	•	weak recommendation, likely to change as data becomes available
	Gastrointestinal Endoscopy (ESGE) e	- · ·	
	guidelines. Endoscopy. 2018 Apr; 50 https://doi.org/10.1055/a-0588-5365	. <i>524</i> – <i>54</i> 0. doi.	
	nttps://doi.org/10.1055/a-0588-5365		

Quality Indicator:

COMP-8.1: IF a patient diagnosed with acute pancreatitis fails to improve clinically within 72 hours of hospital admission, THEN a CECT scan or MRI with contrast should be performed unless contraindicated.

Clinical Recommendation	CECT or MRI is useful for staging disease severity and detecting local complications. It should be considered in patients who fail to improve clinically within 72 hours of hospital admission.	
Performance Target	92.5%	
Indicator Type (Structure/Process/	Process, Efficiency	
Outcome)	Trocess, Efficiency	
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients with acute pancreatitis w	ho do not improve clinically within 72 hours of hospital admission and/or
	Patients with abdominal pain wit	h unclear diagnosis
Rationale (i.e. How does the indicator	CECT scan is the imaging modal	ity of choice to stage disease severity and detect local complications. It has
lead to desired health outcome)?		of close to 100% after 4 days for necrosis. MRI is an excellent alternative for
	patients who cannot undergo CE	CT. This facilitates diagnosis, early assessment of disease severity, prevention
	_	nd prediction of clinical outcomes.
	*Failure to improve clinically: p	ersistent pain, fever, nausea, unable to begin oral feeding
	Supporting Literature	
Source		Methodology and GRADE
1. Tenner S, Baillie J, DeWitt J et al. Am	nerican College of	3- Expert opinion only
Gastroenterology Guideline: Managen	nent of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available
Gastroenterol. 2013 Sep; 108(9):1400-		
2. Kiriyama, Gabata T, Takada T et al. I	_	3- Expert opinion only
pancreatitis. J Hepatobiliary Pancreat Sci 2010; 17: 24 – 36.		Weak recommendation, likely to change as data becomes available
3. Balthazar EJ. Acute pancreatitis: asses	sment of severity with clinical	3- Expert opinion only
and CT evaluation. Radiology 2002; 2	23: 603 – 13.	Weak recommendation, likely to change as data becomes available
4. Bollen TL, Singh VK, Maurer R et al.	•	1C- Observational studies
modified CT severity index and CT se		Intermediate-strength recommendation, may change when stronger evidence
of acute pancreatitis. AJR Am J Roent		is available
5. Arvanitakis M, Dumonceau JM, Albert J, et al. Endoscopic		3- Expert opinion only

management of acute necrotizing pancreatitis: European Society of	Weak recommendation, likely to change as data becomes available
Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary	
guidelines. Endoscopy. 2018 Apr; 50: 524–546. doi:	
https://doi.org/10.1055/a-0588-5365	

Quality Indicator:

COMP-8.2: IF a patient has worsening or persistent abdominal distension in association with severe acute pancreatitis, THEN they should be evaluated for possible abdominal compartment syndrome and if confirmed, managed appropriately.

and if confirmed, managed appropriately.			
Clinical Recommendation	Clinical Recommendation Abdominal compartment syndrome is defined by the World Society of Abdominal Compartment Syndrome		
	(WSACS) as a life-threatening su	stained elevation of the intraabdominal pressure (IAP) that is associated with	
	new onset organ failure or acute worsening of existing organ failure.		
Performance Target	90%		
Indicator Type (Structure/Process/	Process		
Outcome)			
Indicator Level (Hospital/Patient) Patient			
Target Population Patients with severe acute pancre.		atitis	
Rationale (i.e. How does the indicator		ne during an episode of acute pancreatitis is associated with high mortality and	
lead to desired health outcome)? morbidity.			
Supporting Literature			
	Supportin	g Literature	
Source	Supportin	g Literature Methodology and GRADE	
Source 1. Xu J, Cui Y, Tian X. Early Continuous			
	s Veno-Venous Hemofiltration is	Methodology and GRADE	
1. Xu J, Cui Y, Tian X. Early Continuous	s Veno-Venous Hemofiltration is nal Pressure and Serum	Methodology and GRADE 1C- Observational studies	
Xu J, Cui Y, Tian X. Early Continuous Effective in Decreasing Intra-Abdomin	s Veno-Venous Hemofiltration is nal Pressure and Serum Pancreatitis Patients with	Methodology and GRADE 1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence	
Xu J, Cui Y, Tian X. Early Continuous Effective in Decreasing Intra-Abdomis Interleukin- 8 Level in Severe Acute F	s Veno-Venous Hemofiltration is nal Pressure and Serum Pancreatitis Patients with	Methodology and GRADE 1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence	
Xu J, Cui Y, Tian X. Early Continuous Effective in Decreasing Intra-Abdomis Interleukin- 8 Level in Severe Acute F	s Veno-Venous Hemofiltration is nal Pressure and Serum Pancreatitis Patients with Blood Purif 2017; 44:276-282	Methodology and GRADE 1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence	

	Early continuous veno-venous haemofiltration in the management of severe acute pancreatitis complicated with intra-abdominal hypertension: retrospective review of 10 years' experience. Ann Intensive Care. 2012 Dec 20;2 Suppl 1:S21. doi: 10.1186/2110-5820-2-S1-S21. Epub 2012 Dec 20. PubMed PMID: 23281603; PubMed Central PMCID: PMC3527156.	Intermediate-strength recommendation, may change when stronger evidence is available
5.6.	Mentula P, Leppäniemi A. Position paper: timely interventions in severe acute pancreatitis are crucial for survival. World J Emerg Surg. 2014 Feb 10;9(1):15. doi: 10.1186/1749-7922-9-15. PubMed PMID: 24512891; PubMed Central PMCID: PMC3926684. Pupelis G, Zeiza K, Plaudis H, Suhova A. Conservative approach in the management of severe acute pancreatitis: eight-year experience in a single institution. HPB (Oxford). 2008;10(5):347-55. doi: 10.1080/13651820802140737. PubMed PMID: 18982151; PubMed Central PMCID: PMC2575676.	3- Expert opinion only Weak recommendation, likely to change as data becomes available 1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
7.	Xu J, Tian X, Zhang C, Wang M, Li Y. Management of abdominal compartment syndrome in severe acute pancreatitis patients with early continuous veno-venous hemofiltration. Hepatogastroenterology. 2013 Oct;60(127):1749-52. PubMed PMID: 23933789	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available

Quality Indicator:

COMP-8.3: IF a patient with necrotizing pancreatitis has characteristic findings of infection on imaging, or clinically deteriorates, THEN infected necrosis should be suspected and appropriate antibiotics prescribed.

Clinical Recommendation Infected necrosis should be considered in patients with pancreatic or extrapancreatic necrosis who deteriorate		idered in natients with pancreatic or extrapancreatic necrosis who deteriorate or	
		of hospitalization. In these patients, either (i) initial CT-guided fine-needle	
•		and culture to guide use of appropriate antibiotics or (ii) empiric use of	
	antibiotics after obtaining necessary cultures for infectious agents, without CT FNA, should be given.		
Performance Target	98%	sary cultures for infectious agents, without of 11471, should be given.	
Indicator Type (Structure/Process/	Process		
Outcome)			
Indicator Level (Hospital/Patient)	Patient		
Target Population	Patients with acute pancreatitis a	and pancreatic necrosis	
Rationale (i.e. How does the indicator	Infected pancreatic necrosis is as	ssociated with high morbidity and mortality.	
lead to desired health outcome)?			
	Supporting Literature		
Source		Methodology and GRADE	
1. Tenner S, Baillie J, DeWitt J et al. American College of		3- Expert opinion only	
Gastroenterology Guideline: Managen	nent of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available	
Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.			
2. van Dijk SM, Hallensleben NDL, van	Santvoort HC, Fockens P, van	3- Expert opinion only	
Goor H, Bruno MJ, Besselink MG; Du	tch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available	
Acute pancreatitis: recent advances the	ough randomised trials. Gut.		
2017 Nov;66(11):2024-2032. doi: 10.1	136/gutjnl-2016-313595. Epub		
2017 Aug 24. Review. PubMed PMID: 28838972			
2017 Aug 24. Review. PubMed PMID	: 28838972		
2017 Aug 24. Review. PubMed PMID 3. Arvanitakis M, Dumonceau JM, Albe		3- Expert opinion only	
	ert J, et al. Endoscopic	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
3. Arvanitakis M, Dumonceau JM, Albe	ert J, et al. Endoscopic reatitis: European Society of		

https://doi.org/10.1055/a-0588-5365	

Quality Indicator:

COMP-8.4: IF a patient with necrotizing pancreatitis has suspected infection on appropriate intravenous antibiotics and clinically deteriorates, THEN minimally invasive drainage should be performed.

Clinical Recommendation Minimally invasive drainage should be considered as the initial therapy for culture-positive patient	
	surgical intervention reserved for patients in whom treatment fails.
Performance Target 95%	
Indicator Type (Structure/Process/ Process	
Outcome)	
Indicator Level (Hospital/Patient) Patient	
Target Population Patients with acute pancreatitis and peripancreatic fluid collections who have failed IV antibiotic the	
Rationale (i.e. How does the indicator Minimally invasive drainage should be considered before surgical intervention	
lead to desired health outcome)?	

	Supporting Literature		
	Source	Methodology and GRADE	
1.	Baril NB, Ralls PW, Wren SM et al. Does an infected peripancreatic fluid collection or abscess mandate operation? Ann Surg 2000; 231: 361 – 7.	1C- Observational studies Intermediate-strength recommendation, may change when stronger evidence is available	
2.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group Acute pancreatitis: recent advances through randomised trials. Gut. 2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub 2017 Aug 24. Review. PubMed PMID: 28838972	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
3.	Mentula P, Leppäniemi A. Position paper: timely interventions in severe acute pancreatitis are crucial for survival. World J Emerg Surg. 2014 Feb 10;9(1):15. doi: 10.1186/1749-7922-9-15. PubMed PMID: 24512891; PubMed Central PMCID: PMC3926684.	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
4.	Trikudanathan G, Attam R, Arain MA, Mallery S, Freeman ML. Endoscopic interventions for necrotizing pancreatitis. Am J Gastroenterol. 2014 Jul;109(7):969-81; quiz 982. doi:	3- Expert opinion only Weak recommendation, likely to change as data becomes available	

	10.1038/ajg.2014.130. Epub 2014 Jun 24. Review. PubMed PMID: 24957157.	
5	Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA	3- Expert opinion only
	evidence-based guidelines for the management of acute pancreatitis.	Weak recommendation, likely to change as data becomes available
	Pancreatology. 2013 Jul-Aug;13(4 Suppl 2):e1-15. doi:	
	10.1016/j.pan.2013.07.063. PubMed PMID: 24054878.	

Quality Indicator:

COMP-8.5: IF a patient with severe acute pancreatitis demonstrates signs of clinically significant hemorrhage, THEN appropriate workup for potential vascular complications (e.g. pseudoaneurysm and/or thrombosis) should be documented.

Clinical Recommendation A CT angiogram should be ordered		red in any patient with severe acute pancreatitis, who develops sudden	
Chinear Recommendation			
	hemodynamic instability with a drop in hemoglobin without any other overt evidence of GI bleeding.		
Performance Target	97%		
Indicator Type (Structure/Process/	Process		
Outcome)			
Indicator Level (Hospital/Patient)	tal/Patient) Patient		
Target Population	Patients with severe acute pancreatitis suspected to have pseudoaneurysm		
Rationale (i.e. How does the indicator	Pseudoaneurysms typically result from erosion into the gastroduodenal or splenic artery, and may develop in		
lead to desired health outcome)? approximately 10% of patients wi		ith a pancreatic fluid collection. A pseudoaneurysmal bleed may manifest as a	
sudden drop in the hemoglobin, l		nemodynamic instability, or sudden increase in the size of the fluid collection. A	
		a pseudoaneurysm so that appropriate management can be pursued.	
Supporting Literature			
Source		Methodology and GRADE	
We did not find, in our search, literature to	o support this indicator.	3- Expert opinion only	
However, it is, in the opinion of our experi	s, a recommended clinical	Weak recommendation, likely to change as data becomes available	
practice.			

Quality Indicator:

SURG-9.1: IF a patient has acute biliary pancreatitis, THEN surgery should be consulted to consider cholecystectomy prior to discharge.

· · · · · · · · · · · · · · · · · · ·	C	
Clinical Recommendation	•	reatitis, found to have gallstones in the gallbladder, a cholecystectomy should be revent a recurrence of acute pancreatitis.
Indicator Type (Structure/Process/	Process	
Outcome)		
Performance Target	98%	
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients with acute pancreatitis and cholelithiasis	
Rationale (i.e. How does the indicator	Performing a cholecystectomy before discharge prevents recurrence of acute pancreatitis. Recurrence rates for	
lead to desired health outcome)?	acute biliary pancreatitis when cl	holecystectomy is not performed range anywhere from 15% to 61%.
	Supportin	ng Literature
Source		Methodology and GRADE
1. Tenner S, Baillie J, DeWitt J et al. American College of		3- Expert opinion only
Gastroenterology Guideline: Management of Acute Pancreatitis. Am J		Weak recommendation, likely to change as data becomes available
Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.		
2. Ayub K, Slavin J, Imada R. Endoscopic retrograde		1C+ Overwhelming evidence from observational studies
cholangiopancreatography in gallstone-associated acute pancreatitis.		Strong recommendation; can apply to most practice settings in most situations
Cochrane Database of Systematic Reviews. 2004; Issue 3. Art. No.:		
CD003630. DOI: 10.1002/14651858.CD003630.pub2.		
3. Uhl W, Muller CA, Krahenbuhl L et al. Acute gallstone pancreatitis:		2C Observational studies
timing of cholecystectomy in mild and severe disease. Surg Endosc		Very weak recommendation; alternative approaches are likely to be better
1999 1: 1070 – 6.		under some circumstances
4. Somashekar G. Krishna et al. Cholecystectomy during index admission		1C- Observational studies
for gallstone pancreatitis lowers 30-day readmission rates: Analysis of		Intermediate-strength recommendation, may change when stronger evidence
the Nationwide Readmission Database		is available
5. Nguyen GC, Rosenberg M, Chong RY		1C- Observational studies
and ERCP are associated with reduced readmissions for acute biliary		Intermediate-strength recommendation, may change when stronger evidence is available
pancreatitis: a nationwide, population-	based study. Gastrointest Ensoc.	18 available
2012 Jana; 75(1): 47-55		

6.	Kamal A, Akhuemonkhan E, Akshintala V, et al. Effectiveness of Guideline-Recommended Cholecystectomy to Prevent Recurrent Pancreatitis. Am J Gastroenterol 2017 Mar; 112(3): 503-510	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
7.	Da Costa DW, Bouwense SA, Schepers NJ, et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomized controlled trial. Lancet 2015 Sep 26;386 (10000): 1261-1268	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
8.	Aboulian A, Chan T, Yaghoubian A, et al. Early cholecystectomy safely decreases hospital stay in patients with mild gallstone pancreatitis: a randomized prospective study. Ann Surg. 2010; 251: 615 - 19.	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings
9.	Mark C. van Baal et al.Timing of cholecystectomy after mild biliary pancreatitis: A systematic review. Annals of Surgery. 2012; 255: 860 - 866	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
10.	Larson SD, Nealson WH, Evers BM. Management of gallstone pancreatitis. Adv Surg. 2006; 40: 265 - 84.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
11.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group Acute pancreatitis: recent advances through randomised trials. Gut. 2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub 2017 Aug 24. Review. PubMed PMID: 28838972	3 Expert opinion only Weak recommendation, likely to change as data becomes available
12.	Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN; American Gastroenterological Association Institute Clinical Guidelines Committee American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology. 2018 Mar;154(4):1096-1101. doi: 10.1053/j.gastro.2018.01.032. Epub 2018 Feb 3. PubMed PMID: 29409760.	3 Expert opinion only Weak recommendation, likely to change as data becomes available

Care Plan Domain: SURGERY IN ACUTE PANCREATITIS

Quality Indicator:

SURG-9.2: IF a patient has acute biliary pancreatitis complicated by necrosis or peripancreatic fluid collection, THEN cholecystectomy should be deferred until active inflammation subsides and fluid collection(s) resolve or stabilize.

collection(s) resolve or stabilize.			
Clinical Recommendation	In a patient with necrotizing biliary acute pancreatitis, in order to prevent infection, cholecystectomy is to be		
	deferred until active inflammation subsides and fluid collections resolve or stabilize.		
Performance Target	92.5%		
Indicator Type (Structure/Process/	Process		
Outcome)			
Indicator Level (Hospital/Patient)	Patient		
Target Population	Patients with necrotizing gallstone-induced acute pancreatitis and/or peripancreatic fluid collection		
Rationale (i.e. How does the indicator	Adequate time should be given for	or necrosis or peripancreatic fluid collection to stabilize or resolve	
lead to desired health outcome)?	spontaneously. Operating too ea	rly may unnecessarily expose the fluid collection to contaminants, increasing	
	the risk of late infection.		
Supportin		ng Literature	
Source		Methodology and GRADE	
1. Uhl W, Muller CA, Krahenbuhl L et a	l. Acute gallstone pancreatitis:	1C Observational studies	
timing of cholecystectomy in mild and	l severe disease. Surg Endosc	Intermediate-strength recommendation, may change when stronger evidence	
1999 1: 1070 – 6.		is available	
2. Nealon WH, Bawduniak J, Walser EM. Appropriate timing of cholecystectomy in patients who present with moderate to severe gallstone-associated acute pancreatitis with peripancreatic fluid collections. Ann Surg. 2004; 239: 741–49.		1C Observational studies	
		Intermediate-strength recommendation, may change when stronger evidence	
		is available	

Care Plan Domain: SURGERY IN ACUTE PANCREATITIS

Quality Indicator:

SURG-9.3: IF a patient has an asymptomatic pseudocyst(s) and pancreatic and/or extra-pancreatic necrosis, THEN drainage interventions should not be performed.

necrosis, THEN drainage interventions should not be performed.			
		pancreatic and / or extrapancreatic necrosis do not warrant intervention	
regardless of size, location, and /		or extension.	
Performance Target	Performance Target 10%		
Indicator Type (Structure/Process/	Process		
Outcome)			
Indicator Level (Hospital/Patient)	Patient		
Target Population	Patients with asymptomatic pseu	docyst(s) and pancreatic and / or extra-pancreatic necrosis	
Rationale (i.e. How does the indicator	Avoids surgical complications		
lead to desired health outcome)?			
	Supportir	ng Literature	
Source		Methodology and GRADE	
1. Tenner S, Baillie J, DeWitt J et al. An	nerican College of	3 Expert opinion only	
Gastroenterology Guideline: Manager	ment of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available	
Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.			
2. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J		3 Expert opinion only	
Gastroenterol. 2006; 101: 2379 - 400.		Weak recommendation, likely to change as data becomes available	
3. Freeman MF, Werner J, van Santvoor	t HC et al. Interventions for	3 Expert opinion only	
necrotizing pancreatitis. Summary of	a multidisciplinary consensus	Weak recommendation, likely to change as data becomes available	
conference. Pancreas 2012; 8 : 1176 –			
4. Adler DG, Chari ST, Dahl TJ et al. Co	onservative management of	2C Observational studies	
infected necrosis complicating severe	acute pancreatitis. Am J	Very weak recommendation, alternative approaches are likely to be better	
Gastroenterol. 2003; 98: 98 - 103.		under some circumstances	
5. van Santvoort HC, Bakker OJ, Bollen		1C Observational studies	
minimally invasive approach to necrotizing pancreatitis improves the		Intermediate-strength recommendation, may change when stronger evidence	
outcome. Gastroenterology. 2011; 141: 1254 - 63.		is available	
6. Runzi M, Niebel W, Goebell H et al. S	•	2C Observational studies	
surgical treatment of infected necrosis. Pancreas. 2005; 30: 195 - 9.		Very weak recommendation, alternative approaches are likely to be better under some circumstances	
7. Dubner H, Steinberg W, Hill M et al.	Infected pancreatic necrosis and	2C Observational studies	

	peripancreatic fluid collections: serendipitous response to antibiotics and medical therapy in three patients. Pancreas. 1996. 12(3); 298 - 302.	Very weak recommendation, alternative approaches are likely to be better under some circumstances
8.	Hartwig W, Maksan SM, Foitzik T et al. Reduction in mortality with delayed surgical therapy of severe pancreatitis. J Gastrointest Surg. 2002; 6: 481 - 7.	1C Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
9.	Besselink MG, Berwer TJ, Shoenmaeckers EJ et al. Timing of surgical intervention in necrotizing pancreatitis. Arch Surg. 2007; 142: 1194 - 201.	1C Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
10	. Garg PK, Sharma M, Madan K e t al. Primary conservative treatment results in mortality comparable to surgery in patients with infected pancreatic necrosis. Clin Gastroenterol Hepatol. 2010; 8: 1089 - 94.	1C Observational studies Intermediate-strength recommendation, may change when stronger evidence is available
11.	. Mouli VP, Vishnubhatla S, Garg PK. Efficacy of conservative treatment, without necrosectomy, for infected pancreatic necrosis: a systematic review and meta-analysis. Gastroenterology. 2013; 144: 333 – 40.	1C+ Overwhelming evidence from observational studies Strong recommendation; can apply to most practice settings in most situations
12.	. Larson SD, Nealson WH, Evers BM. Management of gallstone pancreatitis. Adv Surg. 2006; 40: 265 - 84.	3 Expert opinion only Weak recommendation, likely to change as data becomes available
13.	. Mentula P, Leppäniemi A. Position paper: timely interventions in severe acute pancreatitis are crucial for survival. World J Emerg Surg. 2014 Feb 10;9(1):15. doi: 10.1186/1749-7922-9-15. PubMed PMID: 24512891; PubMed Central PMCID: PMC3926684.	3- Expert opinion only Weak recommendation, likely to change as data becomes available

Care Plan Domain: SURGERY IN ACUTE PANCREATITIS

Quality Indicator:

SURG-9.4: IF a patient has symptomatic necrotizing pancreatitis, THEN open necrosectomy should not be performed as a first-line treatment.

not be performed as a mist-intercent.			
Clinical Recommendation		y methods for management of necrotic collections have undergone a paradigm	
	shift away from open surgical ne	crosectomy and toward minimally invasive techniques. In symptomatic patients	
	with infected necrosis, minimally invasive methods of necrosectomy are preferred to open necrosectomy		
Performance Target	10%		
Indicator Type (Structure/Process/	Process		
Outcome)			
Indicator Level (Hospital/Patient)	Patient		
Target Population	Patients with acute pancreatitis a	nd symptomatic infected necrosis	
Rationale (i.e. How does the indicator	The traditional approach to the tr	eatment of necrotizing pancreatitis with secondary infection of necrotic tissue is	
lead to desired health outcome)?	open necrosectomy to completely	remove the infected necrotic tissue. This invasive approach is associated with	
	high rates of complications (34 to	95%) and death (11 to 39%) and with a risk of long-term pancreatic	
	insufficiency. As an alternative to	open necrosectomy, less invasive techniques, including percutaneous	
	drainage, endoscopic (transgastri	c) drainage, and minimally invasive retroperitoneal necrosectomy, are	
	increasingly being used.		
	Supportin	g Literature	
Source		Methodology and GRADE	
1. Banks PA, Freeman ML. Practice guid	delines in acute pancreatitis. Am J	3- Expert opinion only	
Gastroenterol. 2006; 101: 2379 - 400.	TIC . 1 I	Weak recommendation, likely to change as data becomes available	
2. Freeman MF, Werner J, van Santvoort	HC et al. Interventions for	1C Observational studies	
necrotizing pancreatitis. Summary of a multidisciplinary consensus		Internal distriction of the second of the se	
• 1	ž	Intermediate-strength recommendation, may change when stronger evidence	
conference. Pancreas 2012; 8:1176 –	94.	is available	
conference. Pancreas 2012; 8 : 1176 – 3. Adler DG, Chari ST, Dahl TJ et al. Co	94. onservative management of	is available 2C Observational studies	
conference. Pancreas 2012; 8: 1176 – 3. Adler DG, Chari ST, Dahl TJ et al. Coinfected necrosis complicating severe	94. onservative management of	is available 2C Observational studies Very weak recommendation, alternative approaches are likely to be better	
conference. Pancreas 2012; 8:1176 – 3. Adler DG, Chari ST, Dahl TJ et al. Coinfected necrosis complicating severe Gastroenterol. 2003; 98: 98 - 103.	94. onservative management of acute pancreatitis. Am J	is available 2C Observational studies Very weak recommendation, alternative approaches are likely to be better under some circumstances	
 conference. Pancreas 2012; 8: 1176 – 3. Adler DG, Chari ST, Dahl TJ et al. Coinfected necrosis complicating severe Gastroenterol. 2003; 98: 98 - 103. 4. van Santvoort HC, Bakker OJ, Bollen 	94. onservative management of acute pancreatitis. Am J T et al. A conservative and	is available 2C Observational studies Very weak recommendation, alternative approaches are likely to be better under some circumstances 1C Observational studies	
 conference. Pancreas 2012; 8: 1176 – 3. Adler DG, Chari ST, Dahl TJ et al. Co-infected necrosis complicating severe Gastroenterol. 2003; 98: 98 - 103. 4. van Santvoort HC, Bakker OJ, Bollen minimally invasive approach to necrot 	94. onservative management of acute pancreatitis. Am J T et al. A conservative and cizing pancreatitis improves the	is available 2C Observational studies Very weak recommendation, alternative approaches are likely to be better under some circumstances 1C Observational studies Intermediate-strength recommendation, may change when stronger evidence	
 conference. Pancreas 2012; 8: 1176 – Adler DG, Chari ST, Dahl TJ et al. Coinfected necrosis complicating severe Gastroenterol. 2003; 98: 98 - 103. van Santvoort HC, Bakker OJ, Bollen minimally invasive approach to necrot outcome. Gastroenterology. 2011; 141 	94. onservative management of acute pancreatitis. Am J T et al. A conservative and cizing pancreatitis improves the : 1254 - 63.	is available 2C Observational studies Very weak recommendation, alternative approaches are likely to be better under some circumstances 1C Observational studies Intermediate-strength recommendation, may change when stronger evidence is available	
 conference. Pancreas 2012; 8: 1176 – 3. Adler DG, Chari ST, Dahl TJ et al. Coinfected necrosis complicating severe Gastroenterol. 2003; 98: 98 - 103. 4. van Santvoort HC, Bakker OJ, Bollen minimally invasive approach to necrot 	94. onservative management of acute pancreatitis. Am J T et al. A conservative and cizing pancreatitis improves the : 1254 - 63. akker OJ et al. A step-up	is available 2C Observational studies Very weak recommendation, alternative approaches are likely to be better under some circumstances 1C Observational studies Intermediate-strength recommendation, may change when stronger evidence	

J Med 2010 Apr 22; 362 (16): 1491 – 502.	
6. Bakker OJ, van Santvoort HC, van Brunschott S et al. Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis; a randomized trial. JAMA 2012; 307: 1053 – 61.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
7. Vege SS, Baron TH. Management of pancreatic necrosis in severe acute pancreatitis. Clin Gastroenterol Hepatol. 2004; 99: 2489 - 94.	2C Observational studies Very weak recommendation, alternative approaches are likely to be better under some circumstances
 8. van Baal MC, van Santvoort HC, Bollen 9. TL et al. Systematic review of percutaneous catheter drainage as primary treatment for necrotizing pancreatitis. Br J Surg. 2011; 98: 18 - 27. 	3- Expert opinion only Weak recommendation, likely to change as data becomes available
10. Larson SD, Nealson WH, Evers BM. Management of gallstone pancreatitis. Adv Surg. 2006; 40: 265 - 84.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
11. van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group Acute pancreatitis: recent advances through randomised trials. Gut. 2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub 2017 Aug 24. Review. PubMed PMID: 28838972	3 Expert opinion only Weak recommendation, likely to change as data becomes available
12. Mentula P, Leppäniemi A. Position paper: timely interventions in severe acute pancreatitis are crucial for survival. World J Emerg Surg. 2014 Feb 10;9(1):15. doi: 10.1186/1749-7922-9-15. PubMed PMID: 24512891; PubMed Central PMCID: PMC3926684.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
13. Trikudanathan G, Attam R, Arain MA, Mallery S, Freeman ML. Endoscopic interventions for necrotizing pancreatitis. Am J Gastroenterol. 2014 Jul;109(7):969-81; quiz 982. doi: 10.1038/ajg.2014.130. Epub 2014 Jun 24. Review. PubMed PMID: 24957157.	3- Expert opinion only Weak recommendation, likely to change as data becomes available
14. van Brunschot S, van Grinsven J, van Santvoort HC, Bakker OJ, Besselink MG, Boermeester MA, Bollen TL, Bosscha K, Bouwense SA, Bruno MJ, Cappendijk VC, Consten EC, Dejong CH, van Eijck CH, Erkelens WG, van Goor H, van Grevenstein WMU, Haveman JW, Hofker SH, Jansen JM, Laméris JS, van Lienden KP, Meijssen MA, Mulder CJ, Nieuwenhuijs VB, Poley JW, Quispel R, de Ridder RJ, Römkens TE, Scheepers JJ, Schepers NJ, Schwartz MP, Seerden T, Spanier BWM, Straathof JWA, Strijker M, Timmer R, Venneman NG, Vleggaar FP, Voermans RP, Witteman BJ, Gooszen HG, Dijkgraaf MG, Fockens P; Dutch Pancreatitis Study Group Endoscopic or	1A/1B- Randomized trials without/with important limitations Strong recommendation; likely to apply to most clinical settings

surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial. Lancet. 2018 Jan 6;391(10115):51-58.	
doi: 10.1016/S0140-6736(17)32404-2. Epub 2017 Nov 3. PubMed PMID: 29108721.	
15. Chang YC. Is necrosectomy obsolete for infected necrotizing	3- Expert opinion only
pancreatitis? Is a paradigm shift needed? World J Gastroenterol. 2014	Weak recommendation, likely to change as data becomes available
Dec 7;20(45):16925-34. doi: 10.3748/wjg.v20.i45.16925. Review.	
PubMed PMID: 25493005; PubMed Central PMCID: PMC4258561.	
16. Arvanitakis M, Dumonceau JM, Albert J, et al. Endoscopic	3- Expert opinion only
management of acute necrotizing pancreatitis: European Society of	Weak recommendation, likely to change as data becomes available
Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary	
guidelines. Endoscopy. 2018 Apr; 50: 524–546. doi:	
https://doi.org/10.1055/a-0588-5365	

Quality Indicator:

STRU-10.1: IF a patient is diagnosed with acute pancreatitis and has the following, THEN the severity should be classified and documented as moderately severe acute pancreatitis:

- a. Organ failure that resolves within 48 hours (transient organ failure) and/or
- b. Local or systemic complications without persistent organ failure

b. Local of systemic complications without persistent organitatione			
· · · · · · · · · · · · · · · · · · ·		titis is characterized by the presence of transient organ failure or local or	
	systemic complications in the ab	sence of persistent organ failure.	
Performance Target	Formance Target 92.5%		
Indicator Type (Structure/Process/ Process			
Outcome)			
Indicator Level (Hospital/Patient) Patient			
Target Population	Patients with acute pancreatitis		
Rationale (i.e. How does the indicator	Early identification of patients w	ith moderately severe disease could potentially limit complications and risk of	
lead to desired health outcome)?	mortality		
	Supportin	ng Literature	
Source		Methodology and GRADE	
1. Tenner S, Baillie J, DeWitt J et al. Am	nerican College of	3- Expert opinion only	
Gastroenterology Guideline: Managen	nent of Acute Pancreatitis. Am J	Weak recommendation, likely to change as data becomes available	
Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.			
2. Banks PA, Bollen TL, Dervenis C et a	l. Classification of acute	3- Expert opinion only	
pancreatitis 2012: revision of Atlanta of	classification and definitions by	Weak recommendation, likely to change as data becomes available	
international consensus. Gut 2013; 62: 102 – 11.			
3. Dellinger EP, Forsmark CE, Layer P e	et al. Determinant-Based	3- Expert opinion only	
Classification of Acute Pancreatitis Se	verity: An International	Weak recommendation, likely to change as data becomes available	
Multidisciplinary Consultation. Ann Surg 2012; 256: 875 – 880.			
4. Forsmark CE, Baillie J; AGA Institute	Clinical Practice and Economics	3- Expert opinion only	
Committee.; AGA Institute Governing	Board AGA Institute technical	Weak recommendation, likely to change as data becomes available	
review on acute pancreatitis. Gastroen	terology. 2007 May;132(5):2022-		
44. Review. PubMed PMID: 1748489	4.		
5. van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van		3- Expert opinion only	

	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
	Acute pancreatitis: recent advances through randomised trials. Gut.	
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub	
	2017 Aug 24. Review. PubMed PMID: 28838972	
6	. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN;	3 Expert opinion only
	American Gastroenterological Association Institute Clinical Guidelines	Weak recommendation, likely to change as data becomes available
	Committee American Gastroenterological Association Institute	
	Guideline on Initial Management of Acute Pancreatitis.	
	Gastroenterology. 2018 Mar;154(4):1096-1101. doi:	
	10.1053/j.gastro.2018.01.032. Epub 2018 Feb 3. PubMed PMID:	
	29409760.	

Quality Indicator:

STRU-10.2: IF a patient is diagnosed with acute pancreatitis, and has persistent organ failure (>48 hours), THEN the severity should be classified and documented as severe acute pancreatitis.

•	_	
Clinical Recommendation	Severe acute pancreatitis is characterized by persistent organ failure.	
Performance Target	98%	
Indicator Type (Structure/Process/	Process	
Outcome)		
Indicator Level (Hospital/Patient)	Patient	
Target Population	Patients with acute pancreatitis	
Rationale (i.e. How does the indicator	Early identification of patients with severe disease could potentially limit complications and risk of mortality.	
lead to desired health outcome)?		
Supporting Literature		

	Supporting Literature		
Source		Methodology and GRADE	
1.	Tenner S, Baillie J, DeWitt J et al. American College of Gastroenterology Guideline: Management of Acute Pancreatitis. Am J	3- Expert opinion only Weak recommendation, likely to change as data becomes available	
	Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.	Weak recommendation, mery to change as data secomes available	
2.	Banks PA, Bollen TL, Dervenis C et al. Classification of acute	3- Expert opinion only	
	pancreatitis 2012: revision of Atlanta classification and definitions by	Weak recommendation, likely to change as data becomes available	
	international consensus. Gut 2013; 62: 102 – 11.		
3.	Dellinger EP, Forsmark CE, Layer P et al. Determinant-Based	3- Expert opinion only	
	Classification of Acute Pancreatitis Severity: An International	Weak recommendation, likely to change as data becomes available	
	Multidisciplinary Consultation. Ann Surg 2012; 256: 875 – 880.		
4.	Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics	3- Expert opinion only	
	Committee.; AGA Institute Governing Board AGA Institute technical	Weak recommendation, likely to change as data becomes available	
	review on acute pancreatitis. Gastroenterology. 2007 May;132(5):2022-		
	44. Review. PubMed PMID: 17484894.		
5.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3- Expert opinion only	
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available	
	Acute pancreatitis: recent advances through randomised trials. Gut.		
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub		
	2017 Aug 24. Review. PubMed PMID: 28838972		

7.	Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN;	3 Expert opinion only
	American Gastroenterological Association Institute Clinical Guidelines	Weak recommendation, likely to cl
	Committee American Gastroenterological Association Institute	
	Guideline on Initial Management of Acute Pancreatitis.	
	Gastroenterology. 2018 Mar;154(4):1096-1101. doi:	
	10.1053/j.gastro.2018.01.032. Epub 2018 Feb 3. PubMed PMID:	
	29409760.	

Weak recommendation, likely to change as data becomes available

Quality Indicator:

STRU-10.3: IF a patient is diagnosed with severe acute pancreatitis, THEN the patient should be managed in a center with expertise in surgery, pancreaticobiliary endoscopy, interventional radiology, intensive care, and nutrition or transferred to a center that does.

Clinical Recommendation	Patients with severe pancreatitis should be managed in a multidisciplinary setup with the availability of		
	surgeons, gastroenterologists, radiologists, intensivists and dietitians.		
Performance Target	90%		
Indicator Type (Structure/Process/	Structure of Care		
Outcome)			
Indicator Level (Hospital/Patient)	Hospital		
Target Population	NA		
Rationale (i.e. How does the indicator	Patients with severe pancreatitis should be managed in a multidisciplinary setup with the availability of		
lead to desired health outcome)?	surgeons, gastroenterologists, radiologists, and intensivists. An early identification of patients with severe		
	pancreatitis and those likely to develop complications and transfer to an appropriate facility is imperative.		
	Outcomes have improved with multidisciplinary management and prudent use of minimal invasive techniques.		
Supporting Literature			
Source		Methodology and GRADE	
1. da Costa DW, Boerma D, van Santvoort HC. Staged multidisciplinary		3- Expert opinion only	
step-up management for necrotizing pancreatitis.Br J Surg		Weak recommendation, likely to change as data becomes available	
2014;101:e65-79. [PMID: 24272964] (Source 53, page)			

Quality Indicator:

STRU-10.4: IF an institution manages patients with acute pancreatitis, THEN the hospital should

have EUS/ERCP services available, or a transfer agreement with a facility that has those capabilities.							
Clinical Recommendation	al Recommendation Hospitals managing patients with acute pancreatitis should have endoscopic capabilities.						
Performance Target	98%						
Indicator Type (Structure/Process/	Structure of Care						
Outcome)							
Indicator Level (Hospital/Patient)	Hospital						
Target Population	NA						
Rationale (i.e. How does the indicator	Endoscopy plays a pivotal role ir	the management of acute pancreatitis; especially in emergent cases such as					
lead to desired health outcome)?	cholangitis and biliary obstructio	on					
Supporting Literature							
Source		Methodology and GRADE					
1. Tenner S, Baillie J, DeWitt J et al. American College of Gastroenterology Guideline: Management of Acute Pancreatitis. Am J		3- Expert opinion only					
		Weak recommendation, likely to change as data becomes available					
Gastroenterol. 2013 Sep; 108(9):1400	-15; 1416.						
Gastroenterol. 2013 Sep; 108(9):1400 2. Tenner S. Initial management of acute		3- Expert opinion only					
	pancreatitis: critical decisions	3- Expert opinion only Weak recommendation, likely to change as data becomes available					
2. Tenner S. Initial management of acute	pancreatitis: critical decisions enterol 2004; 99: 2489 – 94.						

Fundamentals, Second Edition. Edited by Peter B. Cotton and Joseph Leung. 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley & Sons, Ltd.

4. Ayub K, Imada R, Slavin J. ERCP in gallstone associated acute pancreatitis. Cochrane Database Syst Rev 2004: CD003630.

5. Kraft M, Lerch MM. Gallstone pancreatitis: when is endoscopic

retrograde cholangiopancreatography truly necessary? Curr Gastroenterol Rep. 2003 Apr;5(2):125-32. Review. 6. Attasaranya S, Fogel EL, Lehman GA. Choledocholithiasis, ascending cholangitis, and gallstone pancreatitis. Med Clin North Am. 2008

Jul;92(4):925-60, x. doi: 10.1016/j.mcna.2008.03.001. Review. 7. Tse F, Yuan Y. Early routine endoscopic retrograde

cholangiopancreatography strategy versus early conservative

Weak recommendation, likely to change as data becomes available

1C+ Overwhelming evidence from observational studies

Strong recommendation, can apply to most practice settings in most situations

3- Expert opinion only

Weak recommendation, likely to change as data becomes available

3- Expert opinion only

Weak recommendation, likely to change as data becomes available

1C+ Overwhelming evidence from observational studies

Strong recommendation, can apply to most practice settings in most situations

	management strategy in acute gallstone pancreatitis. Cochrane Database Syst Rev. 2012 May 16;(5):CD009779. doi: 10.1002/14651858.CD009779.pub2. Review. PubMed PMID: 22592743.	
8.	van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van	3- Expert opinion only
	Goor H, Bruno MJ, Besselink MG; Dutch Pancreatitis Study Group	Weak recommendation, likely to change as data becomes available
	Acute pancreatitis: recent advances through randomised trials. Gut.	
	2017 Nov;66(11):2024-2032. doi: 10.1136/gutjnl-2016-313595. Epub	
	2017 Aug 24. Review. PubMed PMID: 28838972	

Supplement II: Rating Instructions Given to Panelists

The RAND/UCLA (Fitch et al, 2001) suggests panelists adhere to strict criteria when ranking proposed indicators. Please review and adhere to the criteria below as you complete your ratings:

- 1. Rate indicators on a scale of validity from 1 (definitely not valid) to 9 (definitely valid). Validity pertains to the indicator's ability to measure quality of care and its potential to improve clinical practice.
- 2. Do NOT consider cost implications or feasibility of implementation.
- 3. Ratings should be based on your personal clinical judgments and available scientific evidence, and not on what you think other panelists might say or believe.
- 4. The indicators should be viewed from the perspective of an "average" patient who presents to an "average" physician at an "average" hospital.
- 5. Indicators should not necessarily apply to any one specific patient, but rather should pertain to the overall care of acute pancreatitis patients.

Supplement III: Results of Round 2 Post-Meeting Questionnaire

Acute Pancreatitis Task Force on Quality: Post-Meeting Questionnaire* Results (N=12)

Question	Not at all/ a little	Somewhat	Pretty much/ very much
Literature review	n (%)	n (%)	n (%)
How completely did you read it?	1 (8.3)	4 (33.3)	7 (58.3)
How objective was it?	0 (0.0)	2 (16.7)	10 (83.3)
How informative was it?	1 (8.3)	1 (8.3)	10 (83.3)
How much did it influence your first round ratings?	1 (8.3)	4 (33.3)	7 (58.3)
Round 1 Rating (First Online Survey of all Proposed Indicators)			
How easy did you find the task?	2 (16.7)	4 (33.3)	6 (50)
How onerous did you find the task?	4 (33.3)	6 (50)	2 (16.7)
How clear were the instructions?	2 (16.7)	1 (8.3)	9 (75)
How much did it influence your Round 1 ratings? (Due to effects of fatigue, memory, different times to rate, format of instrument, etc)	4 (33.3)	2 (16.7)	6 (50)
How useful did you find the online Qualtrics survey tool?	2 (16.7)	1 (8.3)	9 (75)
Round 2 Rating (On-site panel meeting)			
How well did the moderator function as group leader?	0 (0.0)	0 (0.0)	12 (100)
How informative was the discussion?	0 (0.0)	0 (0.0)	12 (100)
How argumentative was the discussion?	3 (25)	6 (50)	3 (25)
How much did the feedback from the first round ratings influence your second round ratings?	2 (16.7)	2 (16.7)	8 (66.7)
How much did the discussion influence your second round ratings?	0 (0.0)	3 (25)	9 (75)
Overall Experience			
How well do you believe your own ratings reflect the validity of quality indicators for acute pancreatitis (AP)?	0 (0.0)	0 (0.0)	12 (100)
How well do you believe the panel's ratings will reflect the validity of quality indicators for AP?	0 (0.0)	1 (8.3)	11 (91.7)
How much do you believe this panel process can lead to an official set of recommendations for quality indicators in AP?	0 (0.0)	1 (8.3)	11 (91.7)

^{*}Modified from: Wani, S., et al., Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Gastrointest Endosc, 2017. 86(1): p. 1-17.e3.

Supplement IV: List of Acute Pancreatitis Quality Indicators Found to be Not Valid

Not valid acute pancreatitis quality indicators**

No.	Quality Indicator	Validity Median Ranking	Type(s) of measure
1	IF a patient is confirmed to have acute pancreatitis, THEN the time interval between onset of abdominal	7	Process
2	pain and presentation should be documented IF a patient is diagnosed with acute pancreatitis, THEN biochemical testing for diabetes mellitus and	6	Process, Efficiency
3	ketoacidosis should be obtained on admission. IF a patient diagnosed with acute pancreatitis is younger than 35 years and any of the following conditions are met: a) the etiology remains unknown after initial evaluation, b) they have repeated episodes of pancreatitis after the presumed etiologic factor is removed, c) they have a family history of pancreatitis or pancreatic cancer, THEN genetic testing for susceptibility mutations should be initiated.	8	Process
4	IF a patient is diagnosed with acute pancreatitis, and has no physiologic signs of organ failure and no local or systemic complications, THEN the severity should be classified and documented as mild acute pancreatitis.	8	Process
5	IF a patient is diagnosed with acute pancreatitis, THEN a transabdominal ultrasound should be performed on all patients at presentation.	6.5	Process
6	IF a patient is diagnosed with acute pancreatitis with no cardiovascular and/or renal comorbidities, THEN they should receive intravenous fluid replacement with the goal of maintaining urine output ≥ 0.5 ml/kg/h and mean arterial pressure ≥ 70 mm Hg.	7	Process
7	IF a patient is diagnosed with acute pancreatitis with cardiovascular and/or renal comorbidities, THEN normal saline should be the preferred replacement fluid.	6	Process
3	IF a patient is suspected to have severe hypertriglyceridemia-induced acute pancreatitis, THEN triglyceride levels should be obtained on admission and at 24 and 48 hour intervals after admission.	7	Process
9	IF a patient is suspected to have severe hypertriglyceridemia-induced acute pancreatitis, and persistently elevated triglyceride levels >1000 at 48 hours, THEN hematology should be consulted to consider plasmapheresis.	6.5	Process
10	IF a patient presents with hypertriglyceride-induced pancreatitis and has elevated blood sugar levels on presentation, THEN intravenous insulin therapy should be instituted immediately	7	Process
1	IF a patient has gallstone-induced acute pancreatitis and an intermediate probability* of choledocholithiasis, and ERCP expertise at the center is high, THEN cholecystectomy (if applicable) with intraoperative cholangiogram should be performed. *Intermediate probability of CDL: Increased LFTs or CBD > 7 mm	7	Process
12	IF a patient is diagnosed with gallstone-induced acute pancreatitis and cholecystectomy is deferred due to early complications, THEN adjunct imaging (e.g. EUS, MRCP) should be performed to assess for choledocholithiasis before discharge in patients with intermediate probability* for choledocholithiasis. *Intermediate probability of CDL: Increased LFTs or CBD > 7 mm	7	Process
13	IF a patient is diagnosed with biliary pancreatitis and a high probability* of choledocholithiasis, THEN they should undergo ERCP with appropriate endotherapy before discharge.	9	Process, Efficiency
14	*High probability of CDL: Increased LFTs and CBD > 7 mm or CDL noted on imaging IF a patient is diagnosed with acute pancreatitis [regardless of severity], THEN enteral feeding should be initiated within the first 24-48 hours	8	Process, Efficiency
5	IF a patient diagnosed with acute pancreatitis has significant pain that requires analgesia, THEN initial management should be parenteral [non-morphine] narcotics.	7	Process, Appropriateness
16	IF a patient diagnosed with acute pancreatitis resumes oral intake, THEN ongoing pain management should be converted to oral analgesia.	8	Process, Efficiency
7	IF a patient is diagnosed with acute pancreatitis and is suspected to have infected fluid collection, THEN CT or EUS- guided FNA should be performed prior to initiating antibiotics.	5.5	Process, Appropriateness
.8	IF a patient diagnosed with acute pancreatitis has a Modified Marshall score ≥ 2 , THEN they should be admitted to an intensive care unit.	7	Process
9	IF a patient is diagnosed with severe acute pancreatitis and has abdominal compartment syndrome, THEN surgery and nephrology should be consulted for evaluation and treatment.	7.5	Process
20	IF a patient diagnosed with acute pancreatitis has suspected infected or culture - positive peripancreatic fluid collections, THEN appropriate intravenous antibiotics should be initiated.	9	Process
21	IF an institution manages patients with acute pancreatitis, THEN the institution should track and document their average annual case volume IF a patient presents with acute onset upper abdominal pain with epigastric tenderness and acute	7 8	Structure of Care, Outcome Process,
	pancreatitis is suspected, THEN initial diagnostic evaluation (laboratory and imaging) should be completed prior to admission.	0	Efficiency, Structure of Care
23	IF an institution manages patients with acute pancreatitis, THEN a specific etiology should be identified in at least 80% of cases.	7	Structure of Care, Outcome
24	IF an institution manages patients with acute pancreatitis, THEN the institution should track and document their surgeons' annual cholecystectomy case volume	6.5	Structure of Care, Outcome
25	IF an institution manages patients with severe acute pancreatitis, THEN the hospital should have an intensive care unit staffed by critical care specialists.	8.5	Structure of Care
26 **Ind	IF a patient with severe acute pancreatitis is transferred to a tertiary hospital, THEN the time interval between onset of symptoms, first admission, and transfer should be recorded. ictors categorized as not valid either 1) had median ranking < 7 and/or did not meet statistical criteria for expert panel agree	7 ment (i.e. BIO	Structure of Care, Efficiency MED Classical, p-

^{**}Indictors categorized as not valid either 1) had median ranking < 7 and/or did not meet statistical criteria for expert panel agreement (i.e. BIOMED Classical, p-value, and IPRAS) or 2) were eliminated from consideration based on a \ge 80% vote by the expert panel during Round 2.